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ABSTRACT 
 
Striatal circuits exert a crucial role in motor control, being 
triggered by cortical glutamatergic inputs that are, in turn, controlled by 
nigrostriatal dopaminergic innervation. Accordingly, the imbalance of 
motor function characterizing some neurodegenerative diseases can 
either result from dysfunction of the corticostriatal inputs, as occurs in 
Huntington‟s disease, as well as from dysfunction of the nigrostriatal 
system, the neurochemical hallmark of Parkinson‟s disease.  
Both the neuromodulator adenosine and the neurotrophic factor 
GDNF (glial cell line-derived neurotrophic factor) are tightly involved in 
the control of striatal physiology and have been considered as potential 
therapeutic approaches to different neurological diseases.  From the four 
receptor subtypes that mediate adenosine actions - A1, A2A, A2B and A3, 
A2A receptors are of particular relevance in the striatum and are 
abundantly expressed in this brain area. Adenosine A2A receptor 
antagonists are currently a promising anti-Parkinsonian therapy and the 
manipulation of the referred receptor also affords beneficial effects in 
animal models of Huntington‟s disease. The administration of GDNF is 
also profitable in animal models of Parkinson and Huntington‟s diseases 
and, in spite of an intense debate on its clinical benefits and drawbacks, 
several trials pointed out towards a therapeutic potential in Parkinson´s 
disease. Considering that an important role of A2A receptors is their 
ability to tightly control the action of different growth factors, it seemed of 
interest to investigate if GDNF could modulate the activity of the 
nigrostriatal dopaminergic and the corticostriatal glutamatergic systems 
under the influence of adenosine A2A receptors. 
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The final aim of this work was to evaluate the ability of GDNF to 
presynaptically control neurotransmitter - dopamine and glutamate - 
release from the striatum and whether adenosine A2A receptors could 
modulate GDNF effect. By quantifying dopamine release from striatal 
slices and isolated nerve terminals it was possible to establish that 
GDNF (10 ng/ml) enhances dopamine release in a manner dependent 
on A2A receptor activation. In striatal slices, blockade of GABA (-
aminobutyric acid)ergic transmission enhanced the evoked release of 
dopamine, but reduced the effect of GDNF on dopamine release, 
suggesting that part but not all of the excitatory effect of GDNF depends 
upon GABAergic transmission. Curiously, the magnitude of the 
enhancement of dopamine release caused by GDNF in synaptosomes 
(where a crosstalk between different neuronal structures might be 
virtually absent) was similar to that observed in slices upon inhibition of 
GABAergic transmission. Considering the influence of the circuitry upon 
GDNF striatal effects, glutamate release experiments were then carried 
out using isolated nerve terminals, where GDNF (10 ng/ml) also 
facilitated glutamate release in a manner dependent on A2A receptor 
activation. These observations, which provide a first evidence for a 
crosstalk between adenosine A2A receptors and GDNF in the striatum, 
were further supported by in vivo studies. Thus, in vivo electrical 
stimulation of the corticostriatal pathway induced phosphorylation of 
GDNF receptor, and this phosphorylation was prevented by A2A receptor 
antagonism, indicating that stimulation of cortical afferents promotes 
activation of the GDNF receptor effector in the striatum, a process that 
requires co-activation of A2A receptors. 
In order to further clarify the role of GDNF as a presynaptic 
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modulation system, another goal proposed for this thesis was to 
determine which types of striatal nerve terminals are equipped with 
GDNF receptor components, Ret (rearranjed during transfection) and 
GFRα1 (GDNF family receptor alpha 1), their subsynaptic localization, in 
particular their localization in the active zone, where neurotransmitter 
release takes place and to investigate whether Ret and GFRα1 were co-
located with A2A receptors. Morphological studies revealed that a high 
proportion of the nerve endings at the striatum possess Ret and GFRα1, 
mainly located in the presynaptic active zone and in the postsynaptic 
density, with a lower relative abundance in the extrasynaptic fraction of 
nerve terminals. Ret and GFRα1 were mostly located in dopaminergic 
and glutamatergic nerve terminals, where they were found to be co-
located with A2A receptors, in accordance with the functional interplay 
between GDNF and adenosine. Thus, these results unequivocally 
showed that A2A receptors are present in striatal dopaminergic nerve 
terminals, challenging previous ideas that these receptors were absent 
from these terminals. That concept arose from the observation that A2A 
receptors do not directly interfere with dopamine release. However, by 
performing morphological and functional studies, it was possible to show 
in the present work that A2A receptors are present in striatal 
dopaminergic nerve terminals, where they modulate the action of GDNF 
on dopamine release, in spite of the lack of direct influence upon 
dopamine release.  
In conclusion, these observations provide the first functional and 
morphological evidence that GDNF controls nigrostriatal dopaminergic 
and corticostriatal glutamatergic pathways in a manner largely 
dependent on the co-activation of adenosine A2A receptors, which further 
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confirms the role of adenosine as a modulator of modulators. 
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RESUMO 
 
As alterações motoras características de algumas doenças 
degenerativas resultam da disfunção da neurotransmissão em 
determinadas áreas do cérebro. Alterações da neurotransmissão 
glutamatérgica ou dopaminérgica no estriado (aferências provenientes 
do córtex e da substantia nigra, respectivamente), área cerebral 
fundamental no controlo do movimento, estão envolvidas na 
fisiopatologia das doenças de Huntington e de Parkinson, 
respectivamente. 
O neuromodulador adenosina, bem como o factor neurotrófico 
derivado da glia (GDNF, do inglês glial cell line-derived neurotrophic 
factor) exercem um papel relevante na fisiologia do estriado e 
constituem potenciais estratégias terapêuticas em diferentes doenças 
neurológicas. Os receptores A2A da adenosina assumem particular 
importância no estriado e, de modo consonante, dos quatro subtipos de 
receptores que medeiam as acções do modulador - A1, A2A, A2B e A3, a 
sua expressão é quantitativamente preponderante nesta área do 
cérebro. Os antagonistas destes receptores constituem uma estratégia 
terapêutica promissora na doença de Parkinson e os resultados da sua 
manipulação em modelos animais da doença de Huntington sugerem 
potencial terapêutico nesta patologia. Por seu turno, a administração de 
GDNF induziu respostas benéficas em modelos animais das doenças 
de Huntington e de Parkinson e, apesar de um intenso debate em torno 
de benefícios e desvantagens, vários ensaios clínicos reforçam o 
interesse terapêutico da molécula na doença de Parkinson. Atendendo 
a que uma das acções mais importantes da adenosina - por activação 
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dos receptores A2A - consiste na modulação dos efeitos de diversos 
factores de crescimento, esta dissertação teve como objectivo principal 
clarificar as acções do GDNF na transmissão dopaminérgica da nigra e 
glutamatérgica cortical ao estriado (controlo pré-sináptico da libertação 
de dopamina e glutamato), bem como a influência moduladora dos 
receptores A2A da adenosina sobre as referidas acções. 
Os estudos de quantificação da libertação de dopamina 
conduzidos em fatias ou em terminais nervosos isolados de estriado 
mostraram que o GDNF (10 ng/ml) aumenta a libertação do 
neurotransmissor de modo dependente da activação dos receptores 
A2A. Em fatias de estriado, o bloqueio da transmissão GABA (do inglês, 
-aminobutyric acid)érgica aumenta a libertação evocada de dopamina, 
apesar de atenuar o efeito do GDNF na libertação da mesma, o que 
sugere que parte do efeito excitatório do GDNF depende da 
transmissão GABAérgica. Curiosamente, o aumento da libertação de 
dopamina induzido pelo GDNF em sinaptosomas (onde, virtualmente, 
as diferentes estruturas neuroniais não interagem) foi semelhante ao 
observado em fatias após inibição da transmissão GABAérgica. 
Considerando a influência dos circuitos neuroniais nos efeitos do GDNF, 
as experiências de libertação de glutamato foram conduzidas apenas 
em terminais nervosos isolados, preparação biológica em que o GDNF 
(10 ng/ml) aumentou a libertação de glutamato de modo dependente 
dos receptores A2A. Estas observações, que constituem a primeira 
indicação de que os receptores A2A da adenosina modulam efeitos do 
GDNF no estriado, foram confirmadas por estudos in vivo: a 
estimulação eléctrica da via corticoestriatal induziu a fosforilação do 
receptor do GDNF no estriado, e esta fosforilação foi inibida por 
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antagonismo dos receptores A2A da adenosina.  
Com o objectivo de confirmar as acções do GDNF enquanto 
sistema modulador pré-sináptico no estriado, considerou-se relevante 
identificar os tipos de terminais nervosos que expressam as duas 
proteínas que compõem o complexo-receptor do GDNF, Ret (do ingês 
rearranjed during transfection) e GFR1 (do inglês GDNF family receptor 
alpha 1), bem como analisar a sua localização subsináptica (em 
particular na zona activa, onde ocorre a libertação de 
neurotransmissores) e possível co-localização com os receptores A2A da 
adenosina. As observações morfológicas revelaram que uma elevada 
proporção de terminais nervosos expressam as proteínas Ret e GFR1, 
que estas proteínas estão principalmente localizadas nos terminais 
nervosos dopaminérgicos e glutamatérgicos, onde co-localizam com 
receptores A2A, o que reforça a relação funcional estabelecida entre 
GDNF e adenosina. Como os ligandos dos receptores A2A não 
influenciam directamente a libertação de dopamina no estriado, 
estabeleceu-se que estes receptores não seriam expressos nos 
terminais nervosos dopaminérgicos. Esta ideia é contrariada pelos 
resultados morfológicos e funcionais desenvolvidos neste trabalho, que 
permitem concluir que os receptores A2A são expressos no terminal 
nervoso dopaminérgico estriatal, onde modulam a acção do GDNF na 
libertação de dopamina, ao invés de exercerem acção directa na 
libertação do neurotransmissor. 
Concluindo, as observações decorrentes dos estudos funcionais 
e morfológicos descritos nesta dissertação mostram que o GDNF 
controla as vias dopaminérgica nigroestriatal e glutamatérgica 
corticoestriatal de modo dependente da co-activação dos receptores A2A 
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da adenosina, o que confirma o papel da mesma como modulador de 
moduladores. 
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1. INTRODUCTION 
 
The primary focus of neuropharmacology is the development of 
new molecules with ever-improving efficacy and safety for diseases of 
the nervous system. The control of normal movement is maintained by 
multiple, highly interconnected circuits between different brain areas, 
with the striatum playing a key role in the process. The imbalance of 
synaptic transmission to this brain area underlies the pathophysiology of 
neurodegenerative motor diseases, such as Parkinson´s and 
Huntington´s diseases, involving a dysfunction of the main inputs to the 
striatum: dopaminergic innervation from the nigra and glutamatergic 
inputs from the cortex, respectively. Thus, most drugs target synaptic 
activity and the therapeutic potential of such molecules largely depends 
on their ability to reach this limited brain area. A great challenge in 
pharmacological research is to find or re-design molecules able to cross 
the blood-brain barrier or, in alternative, more sophisticated approaches 
to change synaptic activity or physiological processes related to synaptic 
activity.  
Adenosine is an endogenous neuromodulator, which controls 
and integrates a wide range of brain functions through the activation of 
four receptor subtypes - A1, A2A, A2B and A3 (Fredholm et al., 2001a). 
Dysfunction of the adenosine system is involved in different pathologies, 
namely neurodegenerative disorders and the molecule and/or ligands for 
its receptors have been recognized as prime targets for the development 
of new therapeutics for neurological diseases. Adenosine A2A receptor 
antagonists are currently promising anti-Parkinsonian drugs, which 
already underwent phase III clinical trials (LeWitt et al., 2008). The 
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trophic factor GDNF is also crucial to striatal pathophysiology, affording 
beneficial effects in animal models of Parkinson‟s disease (e.g. Gash et 
al., 1996; Tomac et al., 1995a) and in humans (Patel et al., 2005). The 
manipulation of A2A receptors (reviewed in Popoli et al., 2007), as well as 
the administration of GDNF (reviewed in Alberch et al., 2004) afford 
beneficial effects in animal models of Huntington‟s disease. Thus, both 
adenosine and GDNF influence striatal function at the same circuitry 
level. Considering that an important role of A2A receptors is their ability to 
tightly control the action of different growth factors (Diógenes et al., 
2004, 2007; Mojsilovic-Petrovic et al., 2006; Pousinha et al., 2006; 
Wiese et al., 2007; Fontinha et al., 2008; Fernandes et al., 2008), they 
are also good candidates to modulate GDNF effects.  
The main goal of the work reported in this thesis was to 
investigate the influence of GDNF on dopaminergic and glutamatergic 
striatal nerve endings and the ability of adenosine A2A receptors to 
regulate those actions. 
 
1.1. The striatum: neuronal organization  
 
The term striatum includes both the neostriatum (also called the 
dorsal striatum, composed of caudate and putamen) and more ventral 
extensions referred to as ventral striatum (which main component is the 
nucleus accumbens). This brain area is integrated in a group of bilateral 
subcortical nuclei, the basal ganglia, whose major components are the 
neostriatum and the globus pallidus (GP). Figure 1.1.1 shows a 
schematic representation of neural circuitry in the basal ganglia. 
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Figure 1.1.1 - Simplified representation of neural circuitry in the basal ganglia. 
Glutamatergic neurons from the cortex innervate two major types of GABAergic neurons 
in the striatum. One type, which coexpresses the neuropeptides dynorphin (Dyn) and 
substance P (SP), dopamine D1 receptor (D1R) and adenosine A1 receptor (A1R) 
subtypes projects directly to the globus pallidus pars interna (GPi) and substantia nigra 
pars reticulata (SNr) and give rise to the direct pathway. The other type of GABAergic 
neuron gives rise to the indirect pathway, coexpressing enkephalin (Enk), dopamine D2 
receptor (D2R) and adenosine A2A receptor (A2AR) subtypes and projecting indirectly to 
the GPi and SNr by means of the globus pallidus pars externa (GPe) and subthalamic 
nucleus (STn). Dopaminergic neurons in the substantia nigra pars compacta (SNc) 
modulate these striatal outputs. 
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Two other subcortical nuclei, the subthalamic nucleus (STn) and 
substantia nigra (SN), are functionally and anatomically interconnected 
with the neostriatum. The substantia nigra is located in the midbrain and 
has two main parts: the pars compacta (SNc), which contains 
dopaminergic neurons and the pars reticulate (SNr), which contains 
GABAergic neurons. The basal ganglia and associated nuclei are part of 
a neural circuit that receives and processes input from the cerebral 
cortex, and subsequently provides feedback to the cortex (for a review 
see e.g. Bolam et al., 2000).  
More than 90% of striatal neurons are medium-sized GABAergic 
neurons that project out of the striatum and have dense dendritic spines. 
Thus, they are termed medium-size spiny neurons (MSNs). In the dorsal 
striatum, MSNs can be classified into two major subpopulations 
according to their peptide expression: enkephalinergic and 
dynorphinergic neurons (Gerfen, 2004). These neurons give rise to two 
efferent pathways, which connect the striatum with the output structures 
of the basal ganglia, the SNr and the internal segment of the globus 
pallidus (GPi, entopeduncular nucleus in rodents) (Gerfen, 2004). These 
are called direct and indirect pathways, with the direct pathway being 
made of GABAergic dynorphinergic neurons that coexpress substance P 
(SP) directly connecting the striatum with the output structures and the 
indirect pathway consisting of enkephalinergic neurons, which connect 
the striatum with the external segment of the globus pallidus (GPe, 
globus pallidus in rodents), GABAergic neurons that connect the GPe 
with the STn and glutamatergic neurons which connect the STn with the 
output structures (Figure 1.1.1). GPe GABAergic neurons also project 
directly to the output structures without using the STn relay (Gerfen, 
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2004). 
Dendritic spines of the MSNs are the local of convergence of the 
two main striatal inputs, glutamatergic (from cortical, limbic and thalamic 
areas) and dopaminergic (from the mesencephalon, either the SNc or 
the VTA, ventral tegmental area) afferents (see Figure 1.1.2). 
 
Cortico-limbic-thalamic
glutamatergic input
Mesencephalic
dopaminergic input
 
 
Figure 1.1.2 - Schematic representation of the striatal medium spiny neuron (MSN). 
This neuron receives two main inputs: glutamatergic afferents from cortical, limbic and 
thalamic areas and dopaminergic afferents from the mesencephalon. The magnified 
scheme shows a dendritic spine of the MSN and glutamatergic and dopaminergic 
terminals, which make synaptic contact with the head and neck of the dendritic spine, 
respectively.  
 
The morphological organization of the main striatal afferents, with 
glutamatergic and dopaminergic terminals making synaptic contacts with 
the head and the neck of the dendritic spine, respectively, determines 
functional differences: glutamatergic terminals trigger striatal circuits; 
dopaminergic terminals, unable to trigger electrical responses in MSNs 
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in the absence of glutamatergic inputs, exert a crucial modulatory action 
(Gerfen, 2004). Cholinergic interneurons and GABAergic neurons 
constitute the remaining striatal neurons (for a review see e.g. Tepper 
and Bolam, 2004). Striatal sources of GABA (-aminobutyric acid) 
include interneurons (Kawagushi et al., 1995), afferents from other basal 
ganglia structures, such as GPe or SNr (Kita, 1993) and axon collaterals 
from the MSNs themselves (Kita, 1993; Park et al., 1980). 
 
1.2. Dopaminergic and glutamatergic neurotransmission in 
the dendritic spines of the MSNs 
 
Considering that dopamine and glutamate afferents (onto the 
dendritic spines of the MSNs) constitute the major inputs to the striatum 
and are also the focus of the present work, dopaminergic and 
glutamatergic neurotransmission is discussed in detail in the current 
section (1.2). Adenosine is a key element in the control of both 
transmission systems and the presence of its receptors at dopaminergic 
and glutamatergic terminals is briefly referred in this section (1.2). 
However, given its central role in the present thesis, adenosinergic 
transmission will be further described in detail in a separate section 
(1.3). Besides adenosine, several other modulators/transmitters are able 
to control glutamatergic and dopaminergic transmission in the striatum, 
whose study is clearly out of the scope of the present work. However, in 
this context and because this issue will not be discussed anywhere else 
in this dissertation, it is important to notice that: (1) cholinergic receptors 
in the striatum are of both the metabotropic (muscarinic acetylcholine 
receptor, mAChR) and ionotropic families (nicotinic acetylcholine 
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receptors, nAChR) (Exley and Cragg, 2008) and modulate both 
glutamatergic (Pakhotin and Bracci, 2007) and dopaminergic 
transmission (Harsing and Zigmond, 1998, Hersch et al., 1994, Gomeza 
et al., 1999, Jones et al., 2001, Zhou et al., 2001; Rice and Cragg, 2004; 
Zhang and Sulzer, 2004) and that (2) GABA exerts its action via 
ionotropic GABAA and metabotropic GABAB receptors (Olsen and 
Sieghart, 2008) and control dopaminergic transmission (Tepper and Lee, 
2008). 
 
1.2.1. Dopaminergic neurotransmission 
 
In 1978 it was proposed that dopamine acts through the 
activation of two populations of receptors, one coupled to and the other 
independent of adenylyl cyclase (AC) (Spano et al., 1978). In 1979, 
Kebabian and Calne suggested to call D1 to the receptor positively 
coupled to AC and D2 to the receptors independent of AC. 
Subsequently, three novel receptors were characterized - D3 (Sokoloff et 
al., 1990), D4 (van Tol et al., 1991) and D5/D1b (Sunahara et al., 1991; 
Tiberi et al., 1991) - but all subtypes fall into one of the initially proposed 
classification, D1 or D2, according to their AC coupling ability. All these 
receptors are GPCRs (G protein-coupled receptors). D1 and D5/D1b are 
classified as D1-like and couple with Gs/olf proteins, which activate AC 
and whose main signalling pathway is PKA (cAMP-dependent protein 
kinase A); D2, D3 and D4 receptor subtypes are D2-like and coupled to Gi 
protein, which inhibit AC (for a review see, for e.g. Missale et al., 1998). 
  As mentioned above (1.1), MSNs can be classified as 
enkephalinergic and dynorphinergic neurons (Gerfen, 2004), but the 
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differences between these two subpopulations of neurons are not limited 
to their peptide expression. The expression of GPCRs, dopamine and 
adenosine receptors, is also different: GABAergic enkephalinergic 
neurons express predominantly D2 dopamine receptors (and A2A 
adenosine receptors) and dynorphinergic neurons express 
predominantly D1 dopamine receptors (and A1 adenosine receptors) 
(see Figure 1.1.1) (Ferré et al., 1991, 1994, 1997; Fink et al., 1992; 
Gerfen, 2004; Schiffmann et al., 1991a; Schiffmann and 
Vanderhaeghen, 1993; Svenningsson et al., 1999). Relevant for striatal 
pathophysiology are the antagonistic interactions between A1 and D1 
receptors and A2A and D2 receptors, which underlie GABAergic 
dynorphinergic and enkephalinergic neuronal function (Ferré et al., 
1997, 2005). Furthermore, A2A and A1 receptors form heteromers with D2 
and D1 receptors (Canals et al., 2003; Ciruela et al., 2004; Ginés et al., 
2000; Hillion et al., 2002), mainly localized postsynaptically on dendritic 
spines of GABAergic enkephalinergic and dynorphinergic neurons, 
respectively (Ferré et al., 2005). This tight interaction between dopamine 
and adenosine receptors has profound implications in striatal 
pathophysiology (see 1.3.4). 
The typical neuronal arrangement of the striatum, with 
dopaminergic and glutamatergic afferents making synaptic contacts with 
the neck and the head of dendritic spines, constitutes a functional unit 
which allows dopamine to modulate glutamatergic excitatory inputs 
through synaptic transmission to postsynaptic receptors on the MSNs. 
However, dopamine also acts through the stimulation of extra-synaptic 
receptors. D2/4 receptors are commonly found presynaptically at 
glutamatergic (Tarazi et al., 1998a; Bamford et al., 2004b; Brady and 
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O´Donnell, 2004) and dopaminergic terminals (Sesack et al., 1994; 
Usiello et al., 2000) on enkephalin MSNs, where they provide inhibitory 
modulation of glutamatergic inputs (Bamford et al., 2004a; Brady and 
O´Donnell, 2004) and act as auto-receptors (Sesack et al., 1994; Usiello 
et al., 2000), respectively. One of the mechanisms proposed to be 
involved in dopamine release modulation by auto-receptors is their 
heteromerization with ionotropic nicotinic acethylcholine receptors 
(Quarta et al., 2007).  
Besides the negative feedback mechanism of regulation of 
dopamine transmission operated by D2 receptor activation, the 
transmitter release is also regulated by adenosine A1 receptors (Borycz 
et al., 2007) and glutamate receptors presynaptically expressed at the 
dopaminergic nerve terminal (see e.g. Quarta et al., 2004 and also 
1.2.2).  
 
1.2.2. Glutamatergic neurotransmission 
 
 Glutamate is the main excitatory neurotransmitter in the central 
nervous system (CNS), where it is involved in synaptic transmission and 
excitotoxic neuronal cell death underlying several neurological disorders.  
Glutamate-mediated actions depend upon the activation of both 
ionotropic and metabotropic receptors. AMPA (alpha-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid) and NMDA (N-methyl-D-aspartate), 
ionotropic receptors mediate rapid excitatory synaptic transmission and 
are mainly localized at the postsynaptic density (PSD) (Bernard and 
Bolam, 1998) on the MSNs. PSD is a thickening of the postsynaptic 
membrane also composed of a protein lattice which mediates changes 
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underlying synaptic plasticity, namely the phosphorylation and 
redistribution of AMPA receptors (Lee et al., 2003). As it occurs with 
dopamine, glutamate can also activate extrasynaptic receptors at 
glutamatergic and dopaminergic synapses (Gracy and Pickel, 1996; 
Tarazi et al., 1998b; Paquet and Smith, 2003; Galvan et al., 2006). 
Glutamate metabotropic receptors (mGluRs) are GPCRs divided 
into three groups - group I (with two subtypes, mGluR1 and mGluR5), 
coupled to Gq proteins and mainly located postsynaptically in 
glutamatergic terminals (Smith et al., 2000), and groups II and III, Gi/o-
coupled receptors, usually found presynaptically, where they function as 
auto-receptors (Schoepp, 2001). Group I metabotropic receptors are 
also found at dopaminergic synapses, with mGlu5 receptors localized 
peri- and postsynaptically and mGlu1 receptors localized presynaptically 
(Paquet and Smith, 2003), modulating dopamine release (Zhang and 
Sulzer, 2003).  
Besides glutamate receptors, which are expressed at the 
glutamatergic nerve terminal and control neurotransmission, there are 
several receptors involved in the regulation of glutamate release. 
Adenosine A2A receptors are co-localized and exert a synergistic effect 
with mGlu5 receptors in the facilitation of glutamate release (Rodrigues 
et al., 2005). On the other hand, the same receptors co-localize and 
interact negatively with adenosine A1 receptors to modulate glutamate 
release (Ciruela et al., 2006; Quarta et al., 2004). 
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1.3. Adenosine, a modulator of striatal physiology 
 
1.3.1. Overview as a modulator  
 
Adenosine belongs to a family of compounds - purines - that 
have important effects on many biological processes. Ubiquitous in 
nature, it is essential to living cells as a component of nucleic acids 
(thus, determining the genetic code) and as a sensor/regulator of energy 
metabolism, in a way that its formation is closely related to the energy 
consumption of each cell (see Dunwiddie and Masino, 2001; Ribeiro et 
al., 2003). In 1929, when Drury and Szent-Gyorgyi showed that 
adenosine extracted from heart muscle, has pronounced biological 
effects, including heart rate and blood pressure decrease, arterial 
dilatation and inhibition of intestinal contraction, began an intense 
research on purine effects in several biological preparations, including 
neurotransmission studies in the peripheral and central nervous system 
(Burnstock, 2007). Early studies on the electrically-evoked release of 
nucleotides and nucleosides suggested their involvement in intercellular 
transmission (Kuroda and McIlwain, 1973; Pull and McIlwain, 1972; 
Sulakhe and Phillis, 1975) and, just to mention a couple of examples, it 
was shown that adenosine depressed cortical neurons excitability (Phillis 
et al., 1974) and the firing of cerebellar Purkinje cells (Kostopoulos et al., 
1975). Since these first observations on the role of adenosine in the 
nervous system, several studies report and reinforce adenosine actions 
as a modulator of neurotransmission. Besides fast synaptic actions, 
there is increasing interest in adenosine long-term (trophic) role, namely 
in its synergism with trophic factors. In 1996, Hopker et al. showed that 
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adenosine leads to increased striatal neurite outgrowth in co-culture with 
myenteric plexus explants and proposed that it does so either by 
triggering the release of a neuritogenic factor or by acting synergistically 
with the growth factor. Indeed, another important feature of adenosine is 
the ability to control the effect of neurotrophic factors, an action 
mediated by adenosine A2A receptors in the peripheral and central 
nervous systems (Diógenes et al., 2004, 2007; Mojsilovic-Petrovic et al., 
2006; Pousinha et al., 2006; Potenza et al., 2007; Wiese et al., 2007; 
Fontinha et al., 2008; Fernandes et al., 2008). It was observed that 
treatment with adenosine is capable of activating neurotrophic factor 
receptors (activation of tyrosine kinases), even in the absence of their 
ligand (Lee and Chao, 2001). 
Adenosine is now widely recognized as key molecule in the 
nervous system, where it claims a role of modulator of modulators, 
acting through combined presynaptic, postsynaptic and non-synaptic 
actions (Sebastião and Ribeiro, 2000).  
 
1.3.2. Pathways of production, metabolism and transport 
 
The effect of adenosine is mediated by specific cell-surface 
receptors (see 1.3.3.) with variable affinity for adenosine. Their activation 
depends on adenosine concentration, which is mainly regulated by 
metabolism and transport across the plasma membrane. 
Adenosine is a nucleoside whose formation in the CNS occurs 
both intra- and extracellularly by the metabolism of nucleotides through 
the activity of 5´-nucleotidases. The adenosine produced intracellularly is 
released by bidirectional nucleoside transporters, which regulate 
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extracellular adenosine levels. Two major classes of nucleoside 
transport systems have been described in mammalian cells: the 
concentrative system, independent of nucleoside concentration and the 
equilibrative system, which depends on the nucleoside concentration 
gradient across the plasma membrane and appears to dominate in the 
CNS. Several factors determine the intra- or extracellular origin of 
adenosine, namely the neuronal preparation used and the method used 
to induce adenosine release (for a review see Latini and Pedata, 2001). 
For example, adenosine can be produced postsynaptically by MSNs, 
being released by NMDA stimulation (Delaney and Geiger, 1998), or 
metabolized by ecto-nucleotidases from ATP (adenosine 5´-
triphosphate) co-released with glutamate, in situations of increased 
frequency of impulses arriving at the glutamatergic nerve terminal 
(Cunha, 2001). The relevant point is that, as a product of degradation of 
nucleotides, which are the basis of intracellular energy transfer (Lipman, 
1941), adenosine concentration increases in response to an imbalance 
between cellular energy use and supply (see Dunwiddie and Masino, 
2001; Ribeiro et al., 2003). 
Adenosine is mainly degraded by phosphorylation to AMP by 
adenosine kinase (AK) or deamination to inosine by adenosine 
deaminase (ADA) after uptake across the cell membrane of neurons or 
neighbouring cells. Another possible pathway for adenosine inactivation 
is the reversible reaction catalysed by SAH (S-adenosyl homocysteine) 
hydrolase, forming SAH from adenosine and L-homocysteine, but this 
constitutes only a minor pathway of adenosine metabolism in brain 
tissue under basal conditions (Reddington and Pusch, 1983; Latini and 
Pedata, 2001). Figure 1.3.1 shows a schematic representation of the 
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pathways of adenosine formation, metabolism and transport. 
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Figure 1.3.1 - Pathways of adenosine production, metabolism and transport. 
Abbreviations: ADA, adenosine deaminase; AK, adenosine kinase; ET, equilibrative 
transporter; PDE, phosphodiesterase; SAH, S-adenosyl homocysteine (adapted from 
Latini and Pedata, 2001). 
 
1.3.3. Adenosine receptors - an overview from subtypes and 
signalling to distribution, heteromerization and concentration-
dependent function 
 
In 1978 Burnstock proposed the first formal classification of 
“purinergic” receptors, with adenosine as the main natural ligand at the 
proposed P1 class of receptors. It is now established that adenosine 
actions are mediated by four subtypes of GPCRs, A1, A2A, A2B and A3 
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(Fredholm et al., 2001a) and its central effects are primarily attributed to 
A1 and A2A receptors (Dunwiddie and Masino, 2001). These receptors 
can be differentiated based on different pharmacological criteria, namely 
the respective signalling pathway: the A1 receptor mediates a decrease 
in cAMP associated to its coupling to pertussis toxin-sensitive G proteins 
of the Gi and Go family, which inhibit AC (Akbar et al., 1994; Freissmuth 
et al., 1991; Jockers et al., 1994), whereas A2A receptors associate with 
Gs or Golf proteins, which stimulate AC activity and increase cAMP (cyclic 
adenosine 5´-monophosphate) formation (Corvol et al., 2001; Hervé et 
al., 2001; Kull et al., 2000; Olah, 1997). A2A receptors are concentrated 
in the different parts of the striatum in different mammalian species 
(Schiffmann et al., 1991a,b; Schiffmann and Vanderhaeghen, 1993, 
Svenningsson et al., 1999; Rosin et al., 1998, 2003) and constitute the 
main focus of the present thesis. Figure 1.3.2 shows the preferential 
signalling pathway of the adenosine A2A receptor, the cAMP-PKA 
(cAMP-dependent protein kinase) pathway. cAMP activates a PKA and 
A2A receptor-mediated PKA activation leads to changes that have 
implications for neurotransmitter release - PKA phosphorylates different 
proteins of the presynaptic machinery involved in vesicular fusion 
(Leenders and Sheng, 2005), gene expression - by phosphorylating 
CREB (cAMP response element-binding) (Mayr and Montminy, 2001) - 
and synaptic plasticity - for instance, by phosphorylating GluR1 subunit 
of the postsynaptic AMPA receptor at Ser845 (Wolf et al., 2003). 
In addition to this preferential pathway, A2A receptors have also 
been shown to signal through PLC (phospholipase C) (Wirkner et al., 
2000), phosphatidylinositol 3-kinase (PI3K) (Lee and Chao, 2001) and 
MAPK (mitogen-activated protein kinase) pathways (Ferré et al., 2002; 
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Klinger et al., 2002a,b; Seidel et al., 1999; Sexl et al., 1997).  
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Figure 1.3.2 - Major signal transduction pathway used by adenosine A2A receptor: 
cAMP-PKA cascade. Abbreviations: A cyclase, adenylyl cyclase; PKA, protein kinase A; 
MAPK, mitogen-activated protein kinases; CREB, cAMP response element binding 
protein; PMVF, protein machinery involved in vesicular fusion; VDCC, voltage-dependent 
Ca
2+
 channel. 
 
In the striatum, A2A receptors are preferentially located both pre- 
and postsynaptically at glutamatergic synapses, in a strategic position to 
modulate corticostriatal input to the GABAergic enkephalinergic neurons 
(Hettinger et al., 2001; Ciruela et al., 2006). A2A receptors 
presynaptically expressed (Hettinger et al., 2001; Rosin et al., 2003), 
facilitate excitatory glutamatergic (Ciruela et al., 2006; Rodrigues et al., 
2005), inhibitory GABAergic and cholinergic striatal transmission (Jin 
and Fredholm, 1997; Kirk and Richardson, 1994). In contrast with what 
Introduction 
 45 
happens with glutamate, GABA or acetylcholine neurotransmission, the 
release of dopamine from striatal nerve endings is not under the direct 
control of adenosine A2A receptors (Jin et al., 1993; Jin and Fredholm, 
1997; Lupica et al., 1990), which led to the concept that these receptors 
might be absent from striatal dopaminergic nerve endings.  
A2A receptors have a particular pattern of cellular and subcellular 
distribution at the striatum, exhibiting an efficient interplay between its 
own receptors and the receptors for other neurotransmitters, 
neuromodulators or both (Sebastião and Ribeiro, 2000). During 
decades, in the field of adenosine neuromodulation, A2A receptors were 
considered as isolated entities. However, the ability of these receptors to 
form heteromers with other GPCRs, such as dopamine and glutamate 
receptors and heteromers constituted by different adenosine receptor 
subtypes (Ferré et al., 2007a,b) is now established at the anatomic, 
biochemical and functional levels. For instance, at the presynaptic site of 
the glutamatergic synapse, A2A receptors form heteromeric complexes 
with adenosine A1 receptors (Ciruela et al., 2006), which modulate 
glutamate release, triggering the functioning of striatal circuits. At the 
postsynaptic site, A2A receptors form heteromeric complexes with 
dopamine D2 receptors and metabotropic glutamate mGlu5 receptors, 
important in the control of MSNs responsiveness and in the regulation of 
synaptic plasticity (Ferré et al., 2005).  
The activation of a specific adenosine receptor subtype is 
determined by the concentration of adenosine, which varies as a 
function of pathophysiological conditions and neuronal activity in 
general. Under basal conditions, the relatively low extracellular levels of 
adenosine preferentially stimulate A1 receptor, which show a higher 
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affinity for adenosine than A2A receptors (Fredholm et al., 2001b). At the 
presynaptic level, adenosine A1 receptor stimulation in the A1-A2A 
heteromer inhibits glutamatergic neurotransmission (Ciruela et al., 
2006); at the postsynaptic level endogenous dopamine exerts a strong 
tonic activation of D2 receptors in the striatum, which impair the ability of 
A2A receptors to signal (Kull et al., 1999). Thus, there is a preferential D2 
receptor-mediated modulation of the A2A-D2-mGlu5 heteromeric receptor 
complex, which inhibits A2A receptor-induced activation of AC (Hillion et 
al., 2002) (see Figure 1.3.3A). Under conditions of stronger adenosine 
release (see Figure 1.3.3B) is possible to observe a tonic activation of 
A2A receptors. At the presynaptic level, A2A receptor activation in the 
heteromer would block A1 receptor-mediated function and the overall 
result will be a facilitation of glutamate release and, postsynaptically, the 
dominant A2A receptor activation in the A2A-D2-mGlu5 receptor heteromer 
allows gene expression, protein synthesis and plastic changes 
(Schiffmann et al., 2007). In conclusion, A2A receptors, which are 
localized pre- and postsnaptically taking part of different heteromeric 
complexes, play a key role in the functional changes of glutamatergic 
synapses of the enkephalinergic striatal neurons. 
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Figure 1.3.3 - Schematic representation of distribution of pre- and postsynaptic 
A2A receptor-containing heteromeric receptor complexes in the modulation of 
striatal glutamatergic transmission in the GABAergic enkephalinergic neuron. A. 
During weak cortico-limbic-thalamic input adenosine favors a decrease in the probability 
of glutamate release, due to a preferential stimulation of A1 receptors. At the post-
synaptic site, D2 receptor signalling is favored, reducing neuronal excitability and plastic 
changes. B. During strong cortico-limbic-thalamic input, which facilitates A2A and mGlu5 
synergistic activation, the probability of glutamate release increases due to inhibition of 
A1 receptor signalling. At the post-synaptic site, a synergistic A2A–mGlu5 receptor 
interaction counteracts D2 receptor signaling and favors neuronal excitability and 
synaptic plasticity (Adapted from Schiffmann et al., 2007). 
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1.3.4. Pathophysiological involvement and therapeutic potential of 
A2A receptors in the striatum 
 
The particular cellular localization and assembly of A2A receptors 
in specific heteromers (see 1.3.3) support a plethora of actions 
influencing the physiology and dysfunction of the striatum, the rationale 
for their therapeutic potential in some neurodegenerative diseases. 
Parkinson´s disease hallmark is the loss of dopaminergic input to striatal 
output neurons, resulting from a progressive degeneration of 
nigrostriatal neurons, which determines the enhancement of the 
striatopallidal GABAergic signalling and the motor disturbances 
characteristic of the disease. The indirect striatal output pathway 
appears overactive as a result of removal of inhibitory dopaminergic 
tone. After the first studies demonstrating that the administration of 
methylxanthines, which have been later recognized as adenosine 
receptor antagonists, can exert the same behavioral effects as 
dopamine receptor agonists (Fuxe and Ungerstedt, 1974) and the 
colocalization of D2 and A2A receptors (Hillion et al., 2002), physically and 
biochemically involved in adenosine-dopamine antagonistic interactions 
(Ferré et al., 2004), attention was focused on blocking A2A receptors as a 
potential mean of control of the motor imbalance in Parkinson´s disease. 
Motor dysfunction can also result from the imbalance of the 
corticostriatal glutamatergic inputs, as occurs in Huntington´s disease, 
which is characterized by the selective death of the MSNs, resulting in 
the appearance of generalized involuntary movements, the main 
phenotypic alteration of the disease. Since A2A receptors are mainly 
localized on the neurons that degenerate early in Huntington´s disease 
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and since the receptor (density and distribution) pattern changes in the 
early stages of the disease (Glass et al., 2000), they may also be 
involved in its pathogenesis and A2A receptor antagonism can be 
neuroprotective (Popoli et al., 2007).  
The preferential localization of adenosine A2A receptors at pre- 
and postsynaptic levels of the corticostriatal glutamatergic synapses also 
suggests that A2A receptors may play an important role in the regulation 
of synaptic plasticity (Ferré et al., 2005). Presynaptic A2A receptors 
localized in glutamatergic nerve terminals modulate striatal glutamate 
release (Ciruela et al., 2006) and evidence exists for the involvement of 
fluctuations of glutamate release in LTP (long-term potentiation) and 
LTD (long-term depression), prolonged changes in synaptic strength 
(Ronesi et al., 2005; Schulz, 1997; Sola et al., 2004). Instrumental in the 
establishemment of plastic changes in excitatory synapses is the 
recruitment of ionotropic glutamate receptors AMPA to the synapse 
(Luscher et al., 1999; Malinow and Malenka, 2002; Soderlink and 
Derkach, 2000). In the GABAergic dynorphinergic neuron, this 
mechanism involves two initial critical steps: D1 receptor-mediated PKA 
activation, which induces phosphorylation at Ser 845 of the GluR1 
subunit of the AMPA receptor (Wolf et al., 2003) and phosphorylation of 
the MAPK-ERK1/2 (Malinow and Malenka, 2002; Thomas and Huganir, 
2004). However, this mechanism cannot operate in the GABAergic 
enkephalinergic neurons, where dopamine, by acting on D2 receptors, 
inhibits the cAMP-PKA cascade and MAPK (Ferré et al., 2004, 2005; 
Gerfen et al., 2002). In this case, adenosine, by acting on A2A receptors, 
mimics the role of dopamine on D1 receptors.  
Both enkephalinergic and dynorphinergic neurons receive 
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corticostriatal afferents and display excitatory postsynaptic responses to 
corticostriatal stimulation (Kawaguchi et al., 1990). However, cortical 
stimulation selectively activates MAPK in the enkephalinergic neurons 
without activation in dynorphinergic neurons (Berretta et al., 1997; 
Gerfen et al., 2002), further supporting a central role for A2A receptors in 
striatal plastic changes.  
 
1.4. GDNF, another modulation system in the striatum 
 
1.4.1. Brief description and overview as a trophic factor in the CNS  
 
 It was some decades ago that Levi-Montalcini and Hamburger 
discovered the first growth factor, NGF (nerve growth factor), a protein 
required for the survival of certain sympathetic and sensory neurons. 
The discovery represents an important milestone in neurobiology and 
since then on, several other trophic factors were identified. In 1993, Lin 
and coworkers purified and characterized GDNF from the supernatant of 
a rat glial cell line as a potent growth factor, as well as survival factor for 
embryonic SN dopaminergic neurons. Its trophic effects on 
dopaminergic neurons in the adult brain were demonstrated by the 
retrograde axonal transport from dopaminergic terminals to the SN 
(Tomac et al.,1995b). GDNF also promotes the survival, induces 
differentiation and increases the high affinity dopamine uptake of 
dopaminergic neurons from SN in vivo (Hudson et al., 1995; Tomac et 
al., 1995a) and exhibited the ability to prevent neurotoxic insult-induced 
neuronal degeneration (Lapchak et al., 1997a). 
In addition to the well described effects of GDNF on 
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dopaminergic neurons from the nigra, early studies were also extended 
to other neuronal populations, namely to noradrenergic (Arenas et al., 
1995), cholinergic (Lapchak et al., 1997b), Purkinje cells (Mount et al., 
1995) and striatal MSNs (Perez-Navarro et al., 1996). It was also shown 
that GDNF exerts a dose-dependent effect on the survival of 
motoneurons (Henderson et al., 1994; Oppenheim et al., 1995; Houenou 
et al., 1996).  
 Yet in 1993 (Scharr et al.), GDNF mRNA (messenger ribonucleic 
acid) expression was detected both in developmental and neonatal rat 
brain areas and it was find that low GDNF expression is maintained 
throughout life, particularly in the brain (Stromberg et al.).  
GDNF also exerts important roles outside the nervous system. 
For instance, it acts as a morphogen in kidney development and GDNF-
deficient mice do not develop kidneys (Moore et al., 1996; Pichel et al., 
1996; Sanchèz et al., 1996). GDNF also regulates the differentiation of 
spermatogonia. It is expressed in the developing testes, where it 
regulates cell fate of undifferentiated spermatogonial cells (Meng et al., 
2000). However, a steady stream of positive effects of GDNF in the CNS 
and, in particular at the nigrostriatal pathway, has sustained its potential 
as a therapeutic approach to neurodegenerative diseases, with 
Parkinson´s disease receiving much the attention either in pre-clinical 
and clinical trials involving the trophic factor. 
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1.4.2. GDNF receptor-complex - characterization, signalling and 
distribution  
 
GDNF is the first member of a family of proteins termed GDNF 
family ligand (GFL), consisting of GDNF (Lin et al., 1993), neurturin 
(Kotzbauer et al., 1996), artemin (Baloh et al., 1998), and persephin 
(Mildbrandt et al., 1998). The activation of intracellular signalling 
pathways by each ligand requires the presence of two receptor 
components on the target cell: a surface receptor, a small protein 
anchored by a glycosylphosphatidylinositol (GPI)-link to the outer 
plasma membrane, termed GDNF family receptors α-1 to -4; and Ret, 
the transmembrane tyrosine kinase receptor (Bespalov and Saarma, 
2007). All ligands share the same transmembrane receptor Ret, but 
each ligand binds a preferential GFRα surface receptor. However, 
crosstalk between the different ligands and receptors has been 
described (Baloh et al., 1997; Sanicola et al., 1997; Trupp et al., 1998). 
For instance, GDNF binds with high affinity to GFRα1 and with low affinity 
to either GFRα2 or GFRα3 (Airaksinen et al., 1999). Neurturin and artemin 
may crosstalk weakly with GFRα1, while persephin, on the other hand, 
has only been reported binding to GFRα4 (Masure et al., 2000). Durbec 
et al. (1996) showed that GDNF is a ligand for the tyrosine kinase 
receptor Ret and Treanor et al. (1996) and Jing et al. (1996) showed that 
GDNF acts through the GFR1 and further demonstrated that GDNF 
promotes the formation of a physical interaction between GFR1 and 
Ret, with the subsequent phosphorylation of the latest. The following 
signaling model was proposed: first, a homodimeric member of the 
GDNF family binds to the corresponding surface receptor GFRα-(1 to 4), 
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allowing the subsequent interaction of the GFL/GFRα-(1 to 4) complex 
with two molecules of Ret and inducing its homodimerization, 
autophosphorylation and further activation of signaling pathways 
(Treanor et al., 1996; Trupp et al., 1996). Recently, a novel concept of 
GFR-Ret complex activation was proposed, based on the pre-existence 
of monomeric receptor subunits, GFR1 and Ret, in dynamic equilibrium 
with homodimers, heterodimers or heterotetramers (Figure 1.4.1).  
A. B. C.
Active 
heterotetramer
Ret
GDNF
GFR1
Signalling  
Figure 1.4.1 - Mechanisms of GDNF-GFR1-Ret receptor complex activation. There 
are three proposed mechanisms of Ret activation by its ligands. A. GDNF first binds to 
GFR1, then engages a second co-receptor, and the GDNF-(GFR1)2 complex recruits 
two molecules of Ret. Alternatively, following binding to to GFR1, the first molecule of 
Ret is engaged and then additional monomeric GFR1 and Ret are recruited to the 
GDNF-GFR1-Ret complex (Schlee et al., 2006). B. GFR1 and Ret are in a preform 
GFR1-Ret pair by „crosslinking‟ them. C. The GFR1-Ret complex might exist as a 
preformed (GFR1)2(Ret)2 heterotetramer, which acquires a conformational change in 
response to GDNF, becoming competent for signalling (Adapted from Bespalov and 
Saarma, 2007). 
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Thus, three mechanisms of Ret activation by GDNF are 
proposed: (a) GDNF binds to GFR1, a second molecule of GFR1 is 
engaged and this complex recruits two molecules of Ret; alternatively, 
following binding to GFR1, the first molecule of Ret is engaged and then 
additional monomeric GFR1 and Ret are recruited to the GDNF-GFR1-
Ret complex (Schlee et al., 2006); (b) GDNF binds to a preformed 
heterodimer consisting of GFR1 and Ret and recruits another GFR1-
Ret pair; (c) GDNF impinges a conformational change to a preformed 
heterotetramer composed of two molecules GFR and two molecules of 
Ret. 
GDNF induces different signaling pathways, both in Ret-
dependent or Ret-independent manners. When acting through the 
GFRα1-Ret receptor complex (Trupp et al., 1999; Pezeshki et al., 2001), 
these pathways include MAPK-ERK (inducing phosphorylation of CREB) 
(Airaksinen et al., 1999). In the absence of Ret, GFRα1 fails to activate 
the ERK cascade, but allowed ERK-independent phosphorylation of 
CREB (Pezeshki et al., 2001). 
There are several studies at the mRNA expression level, both in 
the developmental and adult brain pointing out a wide distribution for 
both GDNF and its receptors within the striatum. Particularly at the nigral 
dopaminergic pathway to the striatum, most studies show a 
complementary distribution and expression pattern of GDNF and its 
receptor components, with mRNA for GDNF in the striatum and for 
GFR1 and Ret in dopaminergic cells in the adult brain (Trupp et al., 
1996; Golden et al., 1998; Sarabi et al., 2001), consistently with the 
target-derived nature of GDNF. At the protein level in the adult brain, 
Matsuo et al. (2000), found positive neurons for GFR1 widely distributed 
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in several brain areas, but these neurons were particularly abundant in 
areas such as substantia nigra and Wang and coworkers (2008) 
demonstrated the presence of Ret protein in the substantia nigra pars 
compacta. Concerning the corticostriatal pathway, attention has been 
paid to the location at the target striatal cells, reflecting a particular 
interest in GDNF system modulation as an endogenous trophic 
response of striatal cells to excitotoxic insults, accordingly to the well 
described regulation of GDNF and its receptors expression by excitatory 
amino acids (Ho et al., 1995; Marco et al., 2002; Alberch et al., 2002). 
Matsuo et al. (2000), also described a high density of positive neurons 
for GFR1 protein in the motor cortex. 
 
1.4.3. GDNF - pathophysiological involvement and therapeutic 
potential in the striatum 
 
GDNF was originally identified as a potent trophic factor for 
cultured midbrain dopaminergic neurons and exerts an essential role in 
their development and maintenance (Lin et al., 1993). Later, pronounced 
effects on other neuronal subpopulations, namely on the MSNs, the 
striatal neuronal population most vulnerable in Huntington´s disease, 
were also reported (Pérez-Navarro et al., 1996). 
 In rodent and primate models of Parkinson's disease involving 
selective degeneration of dopaminergic neurons, GDNF has been 
shown to be neuroprotective, to promote fiber outgrowth and to improve 
motor function when delivered into the cerebral ventricles or directly into 
the striatum or substantia nigra (Stanford et al., 2007; Björklund et al., 
1997; Gash et al., 1996; Tomac et al., 1995a), as well as 
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microencapsulated in secreting cells implanted in the striatum 
(Grandoso et al., 2007). In a primate model of the disease, it was 
recently shown that GDNF delivered by a viral vector is important to 
protect and maintain grafted fetal dopamine neurons to depleted areas 
(Elsworth et al., 2008). Neural transplantation offers the potential of 
treating Parkinson's disease, but clinical studies have produced minor 
improvements, mainly because transplanted neurons have low survival 
rates, a problem that may be solved by the adequate supply of trophic 
factors. It was recently proposed that the impairment of striatal plasticity 
after dopamine denervation plays a role in Parkinson's disease 
pathology and that viral expression of GDNF may be protective against 
this neurobiological deficit (Chen et al., 2008). Results obtained either in 
an open clinical trial with intraputamenal infusion of GDNF (Gill et al., 
2003; Patel et al., 2005) as well as with postmortem analysis of a patient 
of the same clinical trial (Love et al., 2005) pointed out towards a 
therapeutic potential of GDNF in Parkinson's disease. Even after 
treatment withdrawn, patients still benefit from GDNF administration 
(Slevin et al., 2007). However, an intense debate of the therapeutic 
potential of GDNF in this neurodegenerative disease (Barker, 2006; 
Kotzbauer and Holtzman, 2006) started recently due to the negative 
outcome of a double blind randomized clinical trial also with GDNF 
infusion in the putamen (Lang et al., 2006). Furthermore, GDNF 
triggered an immune response in subjects receiving recombinant human 
glial-derived neurotrophic factor (Tatarewicz et al., 2007). This 
controversy clearly pointed out the need of further laboratory studies to 
clarify GDNF actions on dopaminergic neurons.  
In addition to its potent effects on dopaminergic midbrain 
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neurons, GDNF has also been shown to protect striatal MSNs (Perez-
Navarro et al., 1996), the neuronal population most affected in 
Huntington´s disease. Excitotoxicity has been related with the 
pathogenesis of the disorder (Estrada-Sanchez et al., 2008) and up-
regulation of GDNF and its receptors was observed after excitotoxic 
insults to the striatum (Alberch et al., 2002). In rodent models of 
Huntington´s disease, GDNF given intraventricularly (Araújo et al., 1997) 
or overexpressed by transplanted cells (Pérez-Navarro et al., 1996; 
1999) had been shown to be neuroprotective in behavioral and 
neurochemical parameters deficits characterizing the disease. The 
referred GDNF actions can be related to its ability to regulate 
neurotransmitter release in the striatum. If there is a large body of 
evidence showing the ability of GDNF to mediate dopaminergic 
transmission, its role upon glutamate release was not studied and a 
direct evaluation of GDNF actions on isolated glutamatergic nerve 
endings has not yet been reported so far.  
  
1.5. Aim 
 
The main goal of the present work was to explore the ability of 
adenosine A2A receptors to modulate striatal physiology by regulating 
GDNF effects upon the main inputs - dopaminergic and glutamatergic - 
to the striatum, as well as to reinforce this functional information with 
morphological data on the distribution, localization and colocalization of 
the receptors of both modulation systems, GDNF and adenosine.  Thus, 
the specific objectives of the work are: 
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1. Investigation of the presynaptic role of GDNF in the release of 
dopamine and glutamate from the rat striatum. 
 
2. Investigation of adenosine A2A receptor modulation of GDNF effects. 
 
3. Study of GDNF receptor components distribution among the main 
striatal nerve terminals. 
 
4. Analysis of adenosine A2A receptor and GDNF receptor components 
colocalization at striatal dopaminergic and glutamatergic nerve endings. 
 
The functional interaction between adenosine A2A receptors and 
GDNF (points 1 and 2) was studied using in vitro and in vivo 
approaches.  In order to clarify the presynaptic nature of the A2A 
receptor-mediated effect of GDNF upon neurotransmitter release, in vitro 
studies were carried out by using striatal purified nerve terminals (or 
synaptosomes) and slices. Additionally, it was considered relevant to 
verify if the cortical stimulation, which triggers striatal circuitry, is able to 
recruit GDNF signalling and to investigate the influence of adenosine A2A 
receptors upon this in vivo measurable physiological parameter - GDNF 
Ret receptor phosphorylation. Observations on the distribution of GDNF 
among different striatal terminals, their synaptic and subsynaptic 
localization and colocalization with adenosine A2A receptors (points 3 
and 4) were carried out by performing western blot and 
immunocytochemical analysis. 
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2. MATERIALS AND METHODS 
 
2.1. Animal handling and biological research preparations 
 
2.1.1. Animals used 
 
Adult (3-4 to 6-8 weeks-old) rats (Wistar or Sprague-Dawley) 
were purchased from Harlam Interfauna Iberica, SL (Barcelona, Spain) 
or Charles River Laboratory (Wilmington, MA). The animals were 
handled according to the European guidelines, the Portuguese law and 
the guidelines of the Institutional Care and Use Committee of the 
Intramural Research Program, National Institute on Drug Abuse, NIH. In 
the in vitro studies, the animals were deeply anesthetized (no skin 
pinched reaction while still breathing) with halothane before decapitation. 
In the in vivo experiments, animals were kept anesthetized with 
equithesin during all surgical procedures. 
 
2.1.2. Dissection and preparation of striatal synaptosomes and 
slices for neurotransmitter release experiments 
 
The striatum was dissected free within ice-cold Krebs solution 
containing pargyline (10 μM), composed of (mM): NaCl 124; KCl 3; 
NaH2PO4 1.25; NaHCO3 26; MgSO4 1; CaCl2 2; and glucose 10, 
previously gassed with 95% O2 and 5% CO2, pH 7.4. A synaptosomal 
fraction of the striatum was prepared with slight modifications of the 
technique described elsewhere (Kirk and Richardson, 1994). The 
removed striata were homogenized in ice-cold 0.32 M sucrose solution 
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(containing 1 mM EDTA, 1 mg/ml BSA (bovine serum albumin) and 10 
mM N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid (HEPES), pH 
7.4) at 4°C, and centrifuged at 3000 g for 10 min. The supernatant was 
centrifuged at 14000 g for 12 min. The pellet was resuspended in ice-
cold 45% (v/v) Percoll in Krebs-HEPES-Ringer (KHR) solution (NaCl 140 
mM, EDTA 1 mM, HEPES 10 mM, KCl 5 mM, glucose 5 mM, pH 7.4) 
and centrifuged at 14000 g for 2 min to eliminate free mitochondria and 
glial debris. The top layer was washed twice at 14000 g for 2 min in KHR 
solution at 4°C. When striatal slices were used, these were cut (400 μm 
thick) perpendicularly to the longer axis of the striatum with a McIlwain 
tissue chopper and allowed to recover functionally and energetically for 
at least 1 h in a resting chamber, filled with the same solution, at room 
temperature (22-25°C) (Figure 2.1.1). 
 
A.
C.
B.
 
 
Figure 2.1.1 - Preparation of striatal slices for neurotransmitter release 
experiments. A. Photograph of a rat brain. B. Photograph of a McIlwain tissue chopper. 
C. Photograph of a resting chamber for brain slices. 
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2.1.3. Preparation of striatal punches for western blot analysis  
 
After the cortical stimulation procedure (see 2.2.2) the brains 
were rapidly extracted, frozen in dry ice-cold isopentane, and stored at -
80°C. Subsequently, unilateral tissue punches of the lateral striatum (16 
gauge) at the AP (anterioposterior) level of bregma 0.0 were obtained 
from 1 mm-thick coronal sections cut in the cryostat at -20°C. The rostral 
side of the coronal sections was localized approximately at bregma 0.5 
mm and the caudal side at bregma -0.5 mm (Figure 2.1.2). The tissue 
punches were sonicated for 10-15 s in homogenization buffer (200 mL 
1% sodium dodecyl sulphate (SDS) in deionized ultrapure sterile water) 
to subsequent western blot analysis. 
 
 
 
Figure 2.1.2 - Striatal punches extraction site. Schematic drawing based on the atlas 
Paxinos and Watson (2004). 
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2.1.4. Preparation of striatal slices for immunochemical analysis  
 
Immediately after the offset of cortical stimulation (see 2.2.2), rats 
were deeply anesthetized with equithesin and perfused transcardially 
with 0.1 M PBS (phosphate buffer saline), followed by 4% formaldehyde 
in 0.1 M sodium phosphate monobasic buffer, pH 7.4. Brains were 
postfixed in the same fixative for 2 h and immersed in 20% sucrose/0.1M 
sodium phosphate, pH 7.4, solution for 48h at 4°C. 20 m-thick coronal 
sections were cut at the AP level of bregma 0.0  1.0 mm in a Leica 
(Nussloch, Germany) CM3050S cryostat at -20°C, collected in PBS, and 
stored in anti-freeze-buffered solution (20% ethylene glycol, 10% 
glycerol, and 10% sucrose in PBS) at -80°C until processing (see 2.2.3).  
 
2.1.5. Preparation of total membranes and synaptosomes for 
synaptic localization studies of Ret and GFRα1 
 
To evaluate the synaptic localization of GDNF receptors, the 
density of the two proteins was compared in total membranes from the 
whole striatum and in membranes from purified striatal nerve terminals, 
a strategy previously used to allocate receptors to nerve terminals 
(Rebola et al., 2005). Total membranes from the striatum and Percoll-
purified striatal synaptosomes were prepared as in previous reports (e.g. 
Rebola et al., 2005). Briefly, the two striata from one rat were 
homogenized at 4°C in sucrose solution (0.32 M) containing 50 mM Tris 
(tris(hydroxymethylaminoethane)-HCl, 2 mM EGTA (ethylene glycol 
tetraacetic acid) and 1 mM dithiothreitol, pH 7.6. The resulting 
homogenates were centrifuged at 3000 g for 10 min at 4°C, the 
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supernatants collected and centrifuged at 14000 g for 20 min at 4°C. 
The pellet of one of the samples was taken as the total membrane 
fraction and was resuspended in SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) buffer for Western blot analysis (see 
2.2.5). The pellet of the other sample was resuspended in 1 ml of a 45% 
(v/v) Percoll solution made up in a Krebs solution (composition 140 mM 
NaCl, 5 mM KCl, 25 mM HEPES, 1 mM EDTA (ethylenediamine 
tetraacetic acid) 10 mM glucose, pH 7.4). After centrifugation at 14000 g 
for 2 min at 4ºC, the top layer was removed (synaptosomal fraction), 
washed in 1 ml Krebs solution and resuspended in 10 ml of incubation 
buffer. This mixture was centrifuged at 14000 g for 20 min at 4ºC and the 
pellet corresponded to the synaptosomes. The membranes were 
obtained by resuspension in SDS-PAGE buffer for Western blot analysis 
(see 2.2.5). 
 
2.1.6. Subcellular fractionation of nerve terminals for subsynaptic 
localization studies of Ret and GFRα1 
 
The extrasynaptic, presynaptic active zone and postsynaptic 
fractions from rat striatal synaptosomes were separated as in previous 
reports (Rodrigues et al., 2005). It was previously confirmed that this 
subsynaptic fractionation method allows an over 90% effective 
separation of active zone (synaptosome-associated protein of 25000 
daltons, SNAP25), postsynaptic density (PSD95) and non-active zone 
fraction (synaptophysin) markers and can be used to access the 
subsynaptic distribution of receptors (see Rodrigues et al., 2005). Briefly, 
striata from 10 rats were homogenized at 4ºC in 15 ml of isolation 
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solution (0.32 M sucrose, 0.1 mM CaCl2, 1 mM MgCl2, 0.1 mM 
phenylmethylsulfonylfluoride, PMSF). The concentration of sucrose was 
raised to 1.25 M by addition of 75 ml of 2 M sucrose and 30 ml of 0.1 
mM CaCl2 and the suspension divided into 10 ultracentrifuge tubes. The 
homogenate was overlaid with 8 ml 1.0 M sucrose, 0.1 mM CaCl2 and 
with 5 ml of homogenization solution and centrifuged at 100000 g for 3 h 
at 4ºC. Synaptosomes were collected at the 1.25/1.0 M sucrose 
interface, diluted 1:10 in cold 0.32 M sucrose with 0.1 mM CaCl2 and 
pelleted (15000 g for 30 min at 4ºC). Pellets were resuspended in 1 ml of 
0.32 M sucrose with 0.1 mM CaCl2 and a small sample taken for gel 
electrophoresis. Then, synaptosomal suspension was diluted 1:10 in 
cold 0.1 mM CaCl2 and an equal volume of 2x solubilization buffer (2% 
Triton X-100, 40 mM Tris, pH 6.0) was added to the suspension. The 
membranes were incubated for 30 min on ice with mild agitation and the 
insoluble material (synaptic junctions) pelleted (40000 g for 30 min at 
4ºC). The supernatant (extrasynaptic fraction) was decanted and 
proteins precipitated with 6 volumes of acetone at 20ºC and recovered 
by centrifugation (18000 g for 30 min at 15ºC). The synaptic junctions 
pellet was washed in pH 6.0 solubilization buffer, resuspended in 10 ml 
of 1% Triton X-100 and 20 mM Tris (pH 8.0), incubated for 30 min on ice 
with mild agitation, centrifuged (40000 g for 30 min at 4ºC) and the 
supernatant (presynaptic active zone fraction) processed as above. 
PMSF (1 mM) was added to the suspension in all extraction steps. The 
pellets from the supernatants and the final insoluble pellet (postsynaptic 
density fraction) were solubilized in 5% SDS, the protein concentration 
determined and the samples added to a 1/6 volume of 6x SDS-PAGE 
sample buffer for Western blot analysis (see 2.2.5). 
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2.1.7. Preparation of striatal nerve terminals for localization and 
colocalization studies 
 
The double or triple labelling immunocytochemical analysis to 
quantify the localization of Ret and GFR1 receptors in striatal nerve 
terminals or their co-localization with A2A receptor was performed 
essentially as in previous reports (e.g. Rodrigues et al., 2005). Briefly, 
striatal synaptosomes were obtained through a discontinuous Percoll 
gradient. This procedure for preparation of the synaptosomes is crucial 
to reduce the amount of postsynaptic density material. In fact, 
immunocytochemical analysis of the synaptosomes obtained with this 
discontinuous Percoll gradient showed that less than 1% of the 
synaptophysin-positive elements were labelled by an anti-PSD95 
antibody (Rebola et al., 2005). Briefly, striatal tissue was homogenized 
in a medium containing 0.25 M sucrose and 5 mM TES (pH 7.4). The 
homogenate was spun for 3 min 2000 g at 4ºC and the supernatant 
spun again at 9500 g for 13 min. Then, the pellets were re-suspended in 
8 mL of 0.25 M sucrose and 5 mM TES (pH 7.4) and 2 mL were placed 
onto 3 mL of Percoll discontinuous gradients containing 0.32 M sucrose, 
1 mM EDTA, 0.25 mM dithiothreitol and 3, 10, or 23% Percoll, pH 7.4. 
The gradients were centrifuged at 25000 g for 11 min at 4ºC. The 
synaptosomes were collected between the 10 and 23% Percoll bands, 
they were washed in 15 mL of HEPES buffered medium (140 mM NaCl, 
5 mM KCl, 5 mM NaHCO3, 1.2 mM NaH2PO4, 1 mM MgCl2, 10 mM 
glucose, and 10 mM HEPES, pH 7.4) and recovered by centrifugation at 
22000 g for 11 min at 4ºC.  
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2.2. Experimental procedures 
 
2.2.1. Neurotransmitter release from striatal synaptosomes and 
slices 
 
The release of exogenous, radiolabelled neurotransmitters, 
dopamine and glutamate, was monitored by a continuous superfusion 
technique. Purified nerve terminals (or synaptosomes) are the most 
adequate in vitro experimental model to study presynaptic phenomena, 
since they enable the direct evaluation of nerve terminal function (Raiteri 
and Raiteri, 2000). Some experiments were also performed in striatal 
slices, which are more complex biological preparations, but are also 
adequate to the study of presynaptic events taking place in the 
dopaminergic nerve terminals from neurons with cell bodies localized in 
the nigra, therefore absent from the striatum. Slices were used for 
comparison with isolated nerve endings, since they retain local 
anatomical integrity, allowing additional modulation of 
neurotransmission. 
 [3H]dopamine release from synaptosomes was performed 
according to previous reports with slight modifications (Kirk and 
Richardson, 1994). The synaptosomes were diluted and equilibrated 
with careful oxygenation (95% O2, 5%CO2) at 37°C for 5 min, after which 
5 μCi of [3H]dopamine (Amersham Biosciences) was added to 
synaptosomes for 20 min (loading period). Preloaded synaptosomes 
were transferred into four parallel 900 μl perfusion chambers, kept 
layered over Whatman® GF/C filters and superfused continuously at a 
rate of 0.8 ml/min at 37°C until the end of the experiment. After 
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termination of the 30 min washout period, 2 min samples were 
continuously collected for liquid scintillation assay. The release of 
[3H]dopamine was stimulated by perfusing 20 mM KCl (isomolar 
substitution of Na+ by K+ in the buffer) for 2 min, at 6 min (S1) and 24 min 
(S2) after starting sample collection.  
The release of [3H]glutamate from rat striatal nerve terminals 
prepared using a combined sucrose/Percoll centrifugation protocol was 
performed according to previous reports (see e.g. Rodrigues et al., 
2005). The nerve terminals were equilibrated at 37ºC for 10 min, loaded 
with 0.2 µM [3H]glutamate for 5 min at 37ºC, washed, layered over 
Whatman GF/C filters and superfused (flow rate: 0.8 ml/min) with Krebs 
solution for 20 min before starting collection of the superfusate. The 
synaptosomes were stimulated with 20 mM KCl (isomolar substitution of 
NaCl by KCl in the Krebs solution) at 3 and 9 min after starting sample 
collection (S1 and S2). GDNF was added before S2 onwards and its 
effect quantified by the modification of S2/S1 ratio versus control (i.e. 
absence of GDNF). When testing the action of GDNF in the presence of 
other drugs (CGS 21680, SCH 58261), these drugs were added to the 
perfusion 15 min before starting sample collection and remained in the 
bath up to the end of the experiment; hence, they were present both in 
S1 and S2, and neither drugs modified the S2/S1 ratio versus control.  
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Figure 2.2.1 - [
3
H]neurotransmitter release from striatal synaptosomes. A. 
Photograph of the experimental setup (a cortesy by Sandra H. Vaz). B. Schematic 
representation of the superfusion setup (chambers and collection system). C. Averaged 
time course of [
3
H] dopamine release experiments. Striatal synaptosomes were labelled 
with [
3
H]dopamine as described in Experimental procedures. Release was evoked twice,  
S1 and S2, by chemical stimulation (20 mM KCl, 2 min). GDNF was added to the test 
chambers before S2, as indicated by the horizontal bar (filled circles), whereas it was not 
added to the parallel control chambers (open circles). Time in the abscissa represents 
ending of collecting period for each sample.  
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[3H]dopamine release from striatal slices was assessed as 
previously (Milusheva et al., 1996) with slight modifications. Striatal 
slices prelabeled with [3H]dopamine (5 μCi for a 30 min incubation 
period) were placed into 4 superfusion chambers (1 slice per chamber) 
and superfused (0.6 ml/min) with Krebs solution for 1 hr (washing 
period) before the collection of 1.8 ml (3 min) fractions was begun. Two 
electrical stimulation periods (supramaximal 2ms rectangular pulses at 2 
Hz, for 2 min), were delivered at 9 min (S1) and 42 min (S2) after starting 
sample collection. Whenever testing the effect of GDNF or of any other 
drug on dopamine release, these test drugs were only added before S2 
(at 27 min) after starting sample collection and remained in the bath up 
to the end of the experiment. When testing the action of GDNF in the 
presence of other drugs (CGS 21680, SCH 58261, CGP 55845 and 
bicuculline), these drugs were added to the perfusion 15 min before 
starting sample collection and remained in the bath up to the end of the 
experiment; therefore, they were present both in S1 and S2. The 
radioactivity released from the preparations was measured with a 
Packard 1600 CA liquid scintillation spectrometer and expressed in 
terms of disintegrations per second per milligram of protein (Bq/mg) in 
each chamber.  In order to determine the amount of tritium retained by 
synaptosomes and slices, the filters and the homogenized slices (in Tris-
HCl 50 mM with MgCl2 10 mM, pH 7.4) were also kept for scintillation 
counting. The amount of [3H]neurotransmitter release in each sample 
was expressed as a percentage of the total radioactivity present in the 
preparation at the point of sample collection (fractional release). The 
amount of radioactivity released by stimulation was calculated by 
integration of the area under the peak of evoked tritium release upon 
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subtraction of basal tritium release. Effects (taken as % change) were 
evaluated by modification of the S2/S1 ratios in test (GDNF added before 
S2) and control (no GDNF added) conditions. 
Values are presented as mean ± SEM from n observations, and 
the significance of the means was calculated by the Student´s t test. 
When comparing the effect of GDNF in more than two experimental 
conditions, one way analysis of variance (ANOVA) followed by 
Bonferroni´s test was used; p values of 0.05 or less were considered to 
represent significant differences. Whenever a statistically significant 
difference between the effects of GDNF under two different experimental 
conditions was found, the difference was confirmed by comparing the 
effect of GDNF under those experimental conditions in synaptosomes 
from the same animal. 
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Figure 2.2.2 - [
3
H]dopamine release from striatal slices. A. Photograph of the 
superfusion chambers for brain slices. B. Averaged time course of [
3
H] dopamine 
release experiments. Striatal slices were labelled with [
3
H]dopamine as described in 
Experimental procedures. Release was evoked twice, S1 and S2, by electrical stimulation 
(supramaximal, 2ms pulses, 2 Hz, 2 min). GDNF was added to the test chambers before 
S2, as indicated by the horizontal bar (filled circles), whereas it was not added to the 
parallel control chambers (open circles). Time in the abscissa represents ending of 
collecting period for each sample. 
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2.2.2. Electrode implantation and in vivo electrical cortical 
stimulation 
 
The animals were implanted unilaterally under Equithesin (NIDA 
Pharmacy, Baltimore, MD) anesthesia with bipolar stainless steel 
electrodes, 0.15 mm in diameter (Plastics One, Roanoke, VA) into the 
orofacial area of the lateral agranular motor cortex (3 mm anterior, 3 mm 
lateral and 4.2 mm below to bregma) (Figure 2.2.3). The electrodes and 
a head holder (connected to a swivel during stimulation) were fixed on 
the skull with stainless steel screws and dental acrylic resin.  
Five days after surgery, rats were placed in individual bowl 
chambers and the implanted electrodes were attached to an electrical 
stimulator (Grass S88K; Grass Instruments Co., W. Warwick, RI). Ten 
min before cortical stimulation the animals were given an i.p. (intra-
peritoneal) administration of saline, A2A receptor antagonists, MSX-3 (3 
mg/kg) or caffeine (10 mg/kg) or A1 receptor antagonist, CPT (4.8 
mg/kg) in a volume of 3 ml/kg of body weight. After 10 min of 
habituation, biphasic current pulse trains (pulse 0.1 msec; 150-200 µA, 
100 Hz, 160 msec trains repeating once per second) were delivered 
using two-coupled constant current units (Grass PSIU6; Grass 
Instruments Co.). The intensity was 150 µA for most cases or it was 
increased up to 200 µA, until small jaw movements were observed. The 
cases that failed to show visible somatic movements were excluded from 
additional analysis. In no case did animals display evidence of seizure 
activity from the electrical stimulation. Stimulation was applied for 20 min 
and the animals were killed immediately after the stimulation offset. The 
brains were rapidly extracted, frozen in dry ice-cold isopentane, and 
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stored at -80°C. Subsequently, unilateral tissue punches of the lateral 
striatum were obtained from coronal sections and stored at -80°C until 
their use in western blot analysis.  
In order to verify the correct implantation of electrodes, one slice 
per animal was stained using the cresyl violet technique. Briefly, 
perfused and fixed slices were mounted on a slide, rehydrated (5 min in 
distilled water) and exposed to increasing concentrations of alcohol (50, 
70, 90 and 100%, 5 min each), then to decreasing concentrations of 
alcohol (100, 90, 70, 50% and water, 5 min each) and finally to the stain 
cresyl violet solution (5-10 min). The slices were then dehydrated in 
increasing concentrations of alcohol (50, 70, 90 and 100%, 5 min each) 
and exposed to xylene (5 min). Using the shaft of a tip, a small drop of 
mounting media was applied and a coverslip was slowly lowered onto 
the slide, which was allowed to dry sufficiently (air dry, at least 24 hs). 
A.
B.
 
Figure 2.2.3 - Electrode implantation site. A. Schematic drawing based on the atlas 
Praxinos and Watson (2004). B. Cresyl violet staining of a brain slice to confirm the 
correct implantation of the electrode. 
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2.2.3. Immunocytochemical analysis of striatal slices 
 
The slices (stored at -80ºC) collected after the cortical stimulation 
protocol were rinsed with PBS, incubated with 100 mM sodium 
borohydride and 0.1% hydrogen peroxide in PBS for 10 min, rinsed, and 
incubated in blocking buffer (PBS/0.1% Triton X-100/5% BSA) for 2 h 
before incubation with rabbit polyclonal anti-phospho-Thr202/Tyr204 
ERK1/2 (1:2000 dilution; Cell Signaling Technology, Danvers, MA) in 
blocking buffer for 24 h at 4°C. Sections were washed and incubated in 
1:200 biotinylated goat anti-rabbit antibody (Vector Laboratories, 
Burlingame, CA) for 2 h, then washed and incubated for 2 h in ABC 
reagent (PK-6100; Vector Laboratories), washed again, treated with 0.33 
mg/ml 3,3´-diaminobenzidine, 50 mM ammonium nickel sulfate, and 
0.003% peroxide until development (5-10 min), transferred to PBS, 
mounted onto chrom-alum gelatin-coated slides, air-dried, dehydrated 
through graded ethanols, cleared in xylene, and coverslipped with DPX 
(mixture of xylene and dibutyl phthalate; Fisher Scientific, Tustin, CA). 
Images were acquired using a digital camera (HRC; Zeiss, Gottingen, 
Germany) coupled to an Axioimager A1 microscope (Zeiss).  
 
2.2.4. Immunocytochemical analysis of striatal nerve terminals 
 
The striatal synaptosomes were placed onto coverslips 
previously coated with poly-L-lysine, fixed with 4% paraformaldehyde for 
15 min and washed twice with PBS medium (140 mM NaCl, 3 mM KCl, 
20 mM NaH2PO4, 15 mM KH2PO4, pH 7.4). The synaptosomes were 
permeabilized in PBS with 0.2% Triton X-100 for 10 min and then 
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blocked for 1 h in PBS with 3% BSA and 5% normal rat serum. The 
synaptosomes were then washed twice with PBS and incubated for 1 h 
at room temperature with different mixtures of primary antibodies, 
namely: rabbit anti-Ret (1:100) or rabbit anti-GFR1 (1:100) and mouse 
anti-synaptophysin (1:200) antibodies; anti-Ret or anti-GFR1 and either 
guinea-pig anti-vesicular glutamate transporter type 1 (vGluT1, 1:1000), 
anti-vGluT2 (1:1000), mouse anti-tyrosine hydroxylase (TH, 1:500), 
guinea-pig anti-vesicular GABA transporter (vGAT, 1:1000) or guinea-
pig anti-vesicular acetylcholine transporter (vAChT, 1:500) antibodies; 
anti-Ret or anti-GFR1 together with goat anti-A2A receptor antibody 
(1:200) and either anti-vGluT1 and 2 or anti-TH antibodies; anti-A2A 
receptor antibody and either anti-TH or rat anti-dopamine transporter 
(DAT, 1:500) antibody. For the double immunocytochemical labelling, 
the synaptosomes were then washed three times with PBS with 3% BSA 
and incubated for 1 h at room temperature with AlexaFluor-598 (red)-
labelled donkey anti-guinea pig or anti-rat or anti-goat or anti-mouse or 
anti-rat IgG antibodies (1:200 for each), carefully washed with PBS and 
then incubated for 1 h at room temperature with AlexaFluor-488 (green)-
labelled donkey anti-rabbit or anti-goat IgG antibodies (1:200 for each). 
For the triple immunocytochemical labelling, the synaptosomes were first 
incubated with AlexaFluor-488-labelled donkey anti-goat antibody 
(1:200) and then with a mixture of AlexaFluor-598-labelled donkey anti-
mouse or anti-rat or anti-guinea-pig and AlxaFluor-350 (blue)-labelled 
goat anti-rabbit antibodies (1:200 for each), to avoid recognition of the 
goat anti-rabbit by the donkey anti-goat antibody (see Rodrigues et al., 
2005). It was confirmed that none of the secondary antibodies produced 
any signal in preparations to which the addition of the corresponding 
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primary antibody was omitted. Most importantly, it was confirmed that 
the individual signals in double-labelled fields are not enhanced over the 
signals under single-labelling conditions. After washing and mounting on 
slides with Prolong Antifade, the preparations were visualized in a Zeiss 
Axiovert 200 inverted fluorescence microscope equipped with a cooled 
CCD camera and analyzed with MetaFluor 4.0 software. Each coverslip 
(3 to 4 per experiment) was analyzed by counting three different fields 
and in each field a minimum of 50 individualized elements. The values 
are presented as mean ± SEM of n experiments (i.e. in preparation 
obtained from different rats).  
 
2.2.5. Western blot analysis 
 
After determining the amount of protein, each sample was diluted 
with 5 volumes of SDS-PAGE buffer containing 30% (v/v) glycerol, 0.6 M 
dithiothreitol, 10% (w/v) SDS and 375 mM Tris-HCl pH 6.8, boiled at 95 
ºC for 5 min. These diluted samples and the pre-stained molecular 
weight markers (Amersham, GE Healthcare, Lisbon, Portugal) were 
separated by SDS-PAGE (10% with a 4% concentrating gel) under 
reducing conditions and electro-transferred to polyvinylidene difluoride 
membranes (0.45 µm, from Amersham) in the absence or presence (for 
phosphorylated proteins) of 2% polyvinylpyrrolidone (PVP) and 50 mM 
sodium fluoride. After blocking for 2 h at room temperature with 5% milk 
in Tris-buffered saline, pH 7.6 containing 0.1% Tween 20 (TBS-T), the 
membranes were incubated overnight at 4ºC with the different 
antibodies, namely: rabbit anti Ret (1:500), rabbit anti-GFR1 (1:100), 
rabbit anti-phosphorylated (Ser696) Ret (1:1000), mouse anti-SNAP25 
Material and Methods 
 79 
(1:20,000), mouse anti-PSD95 (1:100,000) or mouse anti-synaptophysin 
(1:20,000). After four washing periods for 10 min with TBS-T containing 
0.5% milk, the membranes were incubated with either alkaline 
phosphatase-conjugated anti-rabbit (1:20,000) or anti-mouse secondary 
antibody (1:10,000) or horseradish peroxidase-conjugated secondary 
goat anti-rabbit antibody in TBS-T containing 1% milk during 90 min at 
room temperature. After five 10 min-washes in TBS-T with 0.5% milk the 
membranes were incubated with Enhanced Chemi-Fluorescence during 
five minutes or with Enhanced Chemi-Luminescence (Amersham 
Biosciences, Piscataway, NJ) before being analysed with a VersaDoc 
3000 (Biorad, Hercules, CA). The membranes were always re-probed to 
confirm the amount of loaded protein by measuring the immunoreactivity 
against α-tubulin. Briefly, the membranes were first incubated for 30 min 
with 40% methanol, then for 1 hour at room temperature with a 0.1 M 
glycine (pH 7.2) solution and then blocked as previously described 
before incubation with mouse anti-β-actin antibody (1:20,000 dilution). 
The membranes were then washed and incubated with the secondary 
antibody as described. Statistical differences were analyzed by one-way 
ANOVA followed by Dunnett‟s multiple comparisons test. 
 
2.3. Reagents, drugs, antibodies and solutions 
 
7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-
triazolol[1,5-c]pyrimidine (SCH 58261), was from Sigma (St. Louis, MO) 
o a generous from S.Weiss (Vernalis, UK). 2-[p-(2-
carboxyethyl)phenethylamino]-5′-N-ethylcarboxamido adenosine (CGS 
21680), 8-cyclopentyl-1,3-dimethylxanthine (CPT), 3,7-dihydro-8-[(1E)-2-
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(3-ethoxyphenyl)ethenyl]-7-methyl-3-[3-(phosphooxy)propyl-1-(2-
propynil)-1H-purine-2,6-dione (MSX-3) and caffeine (anhydrate base) 
were from Sigma (St. Louis, MO). Glial cell linederived neurotrophic 
factor (GDNF) was from Promega (Madison, WI) and [3H]dopamine 
(specific activity 8.80 Ci/mmol) and [3H]glutamate (specific activity 50 
Ci/mmol) were from Amersham (GE Healthcare, Lisbon, Portugal or 
Buckinghamshire, UK). 3-N[1-(S)-(3,4-dichlorophenyl) ethyl]amino-2-(S)-
hydroxypropyl-P-benzyl-phosphinic acid (CGP 55845) and bicuculline 
were from Tocris. 
CGS 21680 and SCH 58261 were made up in 5 and 10 mM 
stock solutions, respectively, in DMSO. GDNF stock solution was 
prepared in distilled water, at a final concentration of 0.1 mg/ml. CGP 
55845 and bicuculline were made up in 10 and 100 mM stock solutions, 
respectively, in DMSO. All aliquots of stock solutions were kept frozen at 
−20 °C until use, except SCH 58261 aliquots, which were kept at 4 °C 
until use. MSX-3, CPT and caffeine were dissolved in sterile saline (with 
a few drops of 0.1 N NaOH for MSX-3; final pH 7.4). 
 The antibodies used were as follows: goat anti-adenosine A2A 
receptor, rabbit anti-GFR1 and rabbit anti-Ret antibodies (Santa Cruz 
Biotechnology, Santa Cruz CA), rabbit anti-phosphorylated Ret (at 
serine 696) antibody (Novus Biologicals, Litlleton CO), guinea-pig anti-
vesicular glutamate transporters type 1 and type 2 (vGluT1,2), guinea-
pig anti-vesicular acetylcholine transporter (vAChT), mouse anti-tyrosine 
hydroxilase (TH), rat anti-dopamine transporter (DAT) and mouse anti-
PSD95 antibodies (Chemicon Europe, Southampton, UK), guinea-pig 
anti-vesicular GABA transporter (vGAT) antibody (Calbiochem, 
Darmstadt, Germany), mouse anti-SNAP25, mouse anti-synaptophysin 
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and mouse anti-β-actin (Sigma-Aldrich Ibérica, Sintra, Portugal), alkaline 
phosphatase-labelled goat anti-rabbit or anti-mouse antibodies 
(Amersham, GE Healthcare, Lisbon, Portugal), AlexaFluor-598-labelled 
donkey anti-guinea pig, anti-rat, anti-goat and anti-mouse, AlexaFluor-
488-labelled donkey anti-rabbit or anti-goat and AlexaFluor-350-labelled 
goat anti-rabbit antibodies (Molecular Probes, Alfagene, Lisbon, 
Portugal). 
 
  
 
 
 
                                                                                  
 
 
 
 
 
R
E
S
U
L
T
S
 
Results 
 
 85 
3. RESULTS 
 
3.1. Adenosine A2A receptor modulation of GDNF effect upon 
the dopaminergic input to the striatum 
 
3.1.1. Rationale of the study 
 
Evidence has been accumulating that supports a facilitatory role 
for GDNF in striatal dopamine release in vivo (Grondin et al., 2003; 
Hebert and Gerhardt, 1997; Smith et al., 2005). This neurotrophic factor 
also exerts an acute effect on the function of midbrain dopaminergic 
neurons in culture, rapidly and reversibly inhibiting A-type potassium 
channels, which leads to an increase of their excitability (Yang et al., 
2001). These GDNF actions can secondarily cause an increase in 
dopamine release in the striatum, but a direct evaluation of GDNF 
actions on isolated dopaminergic nerve endings has not yet been 
reported so far. On the other hand, it is well established that adenosine 
A2A receptors modulate striatal function. A2A receptors are highly 
expressed in the striatum, predominantly in the medium spiny 
striatopallidal output neurons (see Svenningsson et al., 1999). Though 
A2A receptors modulate the release of neurotransmitters from striatal 
nerve endings, namely GABA and acetylcholine (Kirk and Richardson, 
1994) as well as glutamate (Rodrigues et al., 2005), these receptors do 
not directly influence dopamine release at striatal slices (Jin et al., 1993; 
Lupica et al., 1990). It, therefore, seemed of interest to evaluate if GDNF 
could presynaptically modulate dopamine release and if so, whether 
adenosine A2A receptors could modulate that action of GDNF.  
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3.1.2. GDNF enhanced K+-evoked dopamine release from isolated 
nerve terminals 
 
In striatal synaptosomes incubated with [3H]dopamine, the initial 
(first three collected samples) basal release of tritium was 1.73±0.02% of 
the total tritium incorporated in the synaptosomes (fractional release) 
(n=12) (Figure 3.1.1A). The first stimulation period (S1) caused a twofold 
increase in the amount of tritium release, whereas the second caused a 
smaller increase, so that the S2/S1 ratio obtained was 0.56±0.02 (n=12). 
When GDNF (10 ng/ml) was present during S2, the S2/S1 ratio was 
increased to 0.80±0.03 (p<0.05 as compared with the control) (Figure 
3.1.1C), corresponding to a 42±4.8% (n=8) enhancement of tritium 
release (Figure 3.1.2). As shown in Figure 3.1.1B, the facilitation by 
GDNF of the K+-evoked [3H]dopamine release increased with GDNF 
concentration from 3 ng/ml to 30 ng/ml. For the subsequent studies on 
the modulation of the GDNF effect upon dopamine release, the 
intermediate concentration of 10 ng/ml was chosen to avoid a ceiling 
effect; furthermore, concentrations of GDNF causing more than twofold 
increase in dopamine release are not expected to occur endogenously. 
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Figure 3.1.1 - GDNF enhances K
+
-evoked [
3
H]dopamine release from striatal 
synaptosomes. A. Averaged time course of [
3
H]dopamine release experiments. Striatal 
synaptosomes were labeled with [
3
H]dopamine as described in Experimental 
Procedures. Release was evoked twice, S1 and S2, by chemical stimulation (20 mM KCl, 
2 min). GDNF was added to the test chambers before S2, as indicated by the horizontal 
bar (filled circles), whereas it was not added to the parallel control chambers (open 
circles). Time in the abscissa represents ending of collecting period for each sample. 
Each point represents the mean SEM of the results obtained in 8–12 experiments 
performed in duplicate. B. Concentration-response curve for the enhancement of K
+
-
evoked [
3
H]dopamine release caused by GDNF in striatal nerve terminals. The effect of 
GDNF was calculated by comparing the S2/S1 ratio obtained in test (presence of GDNF 
during S2) and in control conditions in the same experiments. Each point represents the 
mean SEM of results obtained in 2 (GDNF 3 and 30 ng/ml) to 8 (GDNF 10 ng/ml) 
experiments. C. S2/S1 ratio obtained in the absence (−) or in the presence (+) of GDNF, 
as indicated below each bar; *p<0.05 as compared with the control (left column, 
Student's t test). 
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3.1.3. GDNF enhancement of K+-evoked dopamine release from 
isolated nerve terminals is dependent on adenosine A2A receptor 
activation 
 
The ability of adenosine A2A receptors to modulate GDNF-
mediated enhancement of dopamine release was evaluated by 
performing experiments where the A2A receptor agonist, CGS 21680, 
was present during S1 and S2 (see Materials and Methods) in all 
perfusion chambers, at a concentration (10 nM) selective for adenosine 
A2A receptors (Jarvis et al., 1989). As before, the effect of GDNF (10 
ng/ml) was evaluated by comparing the S2/S1 ratio obtained in the 
absence of GDNF with the S2/S1 ratio obtained in parallel chambers 
where GDNF was added before S2. Under these conditions, GDNF 
enhanced the evoked release of tritium by 65±2.9% (n=5), an effect 
significantly (p<0.05) greater than that observed in the absence of CGS 
21680 (Figure 3.1.2). We then tested whether blockade adenosine A2A 
receptors with the selective antagonist, SCH 58261, affected the GDNF 
excitatory action. The protocol used was similar to that described above, 
except that SCH 58261 was used instead of CGS 21680. The 
concentration of SCH 58261 (50 nM) used in these experiments was 
100 times higher its Ki value for adenosine A2A receptors and well below 
its Ki for other adenosine receptor subtypes (Zocchi et al., 1996).  
As illustrated in Figure 3.1.2, the GDNF-induced enhancement of 
dopamine release was prevented (p<0.05, n=4) by the A2A receptor 
antagonist, suggesting that the effect of GDNF in striatal dopaminergic 
nerve endings requires tonic activation of adenosine A2A receptors. The 
presence of CGS 21680 (10 nM) or SCH 58261 (50 nM) during S1 and 
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S2 did not appreciably modify the S2/S1 ratio (p>0.05) as compared with 
the ratio obtained in the absence of any drug. 
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Figure 3.1.2 - Ability of the selective A2A receptor agonist, CGS 21680 (10 nM), and 
of the A2A receptor antagonist, SCH 58261 (50 nM), to modify the action of GDNF 
(10 ng/ml) on [
3
H]dopamine release from striatal synaptosomes. Zero percent in the 
ordinates represents the S2/S1 ratio obtained in the absence of GDNF for each 
experimental condition indicated below the bars. Results are mean SEM from n 
experiments performed in duplicate.*p<0.05 as compared with 0% (Student's t test); 
φp<0.05 as compared with the effect of GDNF (10 ng/ml) in the absence of other drugs 
(left column) (one-way ANOVA analysis followed by Bonferroni's test). 
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3.1.4. GDNF enhanced electrically-evoked dopamine release from 
striatal slices 
 
In striatal slices incubated with [3H]dopamine, the initial basal 
fractional release of tritium was 0.91±0.06% (n=10) (Figure 3.1.3A). The 
first stimulation period (S1) caused a nearly threefold increase in the 
amount of tritium release, whereas the second one caused a smaller 
increase, the S2/S1 ratio being 0.70±0.02 (n=10). When GDNF (10 
ng/ml) was present during S2, the S2/S1 ratio increased (p<0.05) up to 
1.3±0.12 (Figure 3.1.3B) corresponding to 89±9.3% (n=10) 
enhancement of tritium release (Figure 3.1.4). 
 
3.1.5. GDNF effect on dopamine release from striatal slices also 
depends upon A2A receptor tonic activation 
 
When A2A receptors were blocked with SCH 58261 (50 nM, in S1 
and S2), the effect of GDNF upon dopamine release was prevented (% 
change by GDNF: 2.6±1.2%, n=4, p<0.05, as compared with the effect 
of GDNF alone) (Figure 3.1.4), indicating that A2A receptors are also 
required for the GDNF effect on dopamine release from striatal slices. 
Surprisingly, the A2A receptor agonist, CGS 21680 (10 nM) decreased 
(n=7, p<0.05) the facilitatory effect of GDNF on dopamine release from 
striatal slices (Figure 3.1.4), in clear contrast with what was observed in 
striatal synaptosomes (Figure 3.1.2). 
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Figure 3.1.3 - GDNF enhances electrically evoked [
3
H]dopamine release from 
striatal slices. A. Averaged time course of [
3
H]dopamine release experiments. Striatal 
slices were labelled with [
3
H]dopamine as described in Experimental Procedures. 
Release was evoked twice, S1 and S2, by electrical stimulation (supramaximal, 2ms 
pulses, 2 Hz, 2 min). GDNF was added to the test chambers before S2, as indicated by 
the horizontal bar (filled circles), whereas it was not added to the parallel control 
chambers (open circles). Time in the abscissa represents ending of collecting period for 
each sample. B. S2/S1 ratio obtained either in the absence and in the presence of GDNF 
as indicated below each bar; *p <0.05 as compared with the control (Student's t test). 
Results are the mean SEM of 10 experiments performed in duplicate. 
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Figure 3.1.4 - Ability of the selective A2A receptor agonist, CGS 21680 (10 nM), and 
of the A2A receptor antagonist, SCH 58261 (50 nM), to modify the action of GDNF 
(10 ng/ml) on [
3
H]dopamine release in striatal slices. Zero percent in the ordinates 
represents the S2/S1 ratio obtained in the absence of GDNF for each experimental 
condition indicated below the bars. Results are mean SEM from n experiments 
performed in duplicate.*p<0.05 as compared with 0% (Student's t test); φp<0.05 as 
compared with the effect of GDNF (10 ng/ml) in the absence of other drugs (left column) 
(one-way ANOVA analysis followed by Bonferroni's test). 
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3.1.6. Influence of A2A receptors and of GABA transmission 
blockers upon dopamine release in striatal slices 
 
GABAergic spiny neurons represent the majority of the cells in 
the striatum (see e.g. Kawaguchi et al., 1995). A2A receptors are 
expressed in those neurons and regulate GABAergic synaptic 
transmission (see Discussion). Furthermore, inhibitory modulation of 
dopamine release by glutamatergic or muscarinic cholinergic 
transmission mostly depends on the activity of GABAergic neurons (Wu 
et al., 2000; Zhang et al., 2002). Therefore, to evaluate if the 
“paradoxical” CGS 21680- induced decrease of the effect of GDNF upon 
dopamine release could be attributed to an influence of A2A receptors in 
the striatal GABAergic circuits, we performed experiments where 
GABAergic transmission was blocked and tested the effect of GDNF in 
the absence and in the presence of the A2A receptor agonist. GABAergic 
transmission was blocked with the GABAA and GABAB receptor 
antagonists, bicuculline (10 μM) and CGP55845 (1 μM); under these 
conditions, GDNF (10 ng/ml, added before S2) enhanced the evoked 
release of tritium by 37±1.8% (n=4). When CGS 21680 (10 nM) was also 
added together with bicuculline (10 μM) and CGP 55845 (1 μM), GDNF 
(10 ng/ml) enhanced the evoked release of tritium by 74±5.6% (n=7, 
p<0.05 as compared with absence of CGS 21680) clearly showing that 
A2A receptor activation enhances the action of GDNF when GABAergic 
transmission is blocked. In slices with GABAergic transmission blocked, 
SCH 58261 (50 nM) prevented the effect of GDNF (10 ng/ml) on the 
evoked release of dopamine (Figure 3.1.5). The presence of SCH 58261 
(50 nM) or CGS 21680 (10 nM) or CGP 55845 (1 μM) plus bicuculline 
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(10 μM) during S1 and S2 did not significantly (p>0.05) influence the 
S2/S1 ratio as compared with absence of any drug. 
In the experiments described above, the fractional release of 
tritium during the first stimulation period (S1) was not significantly 
(p>0.05) modified by the presence of SCH 58261 (50 nM) or CGS 21680 
(10 nM), but it was higher (p<0.05) in the slices where GABAergic 
transmission was blocked with bicuculline (10 μM) and CGP 55845 (1 
μM). This suggested that the evoked release of dopamine was not 
influenced by the A2A receptor agonist or antagonist, but that blockade of 
GABAergic transmission was enhancing dopamine release. To directly 
evaluate the action of these drugs upon dopamine release, experiments 
were designed where they were applied to the slices before S2 and the 
S2/S1 ratios obtained in their presence compared with the S2/S1 ratios 
obtained in the absence of drugs. As expected (see also Lupica et al., 
1990), neither CGS 21680 (10 nM) nor SCH 58261 (50 nM), when 
applied before S2, influenced significantly (p>0.05) the evoked release of 
tritium (%change by CGS: 0.31±4.6, n=4; % change by SCH: -6.8±4.4, 
n=3). Inhibition of GABAergic transmission by the addition of bicuculline 
(10 μM) and CGP 55845 (1 μM) before S2 increased the S2/S1 ratio by 
60±3.7% (p<0.05, n=3), indicating that dopamine release in striatal 
slices is under control of GABAergic transmission. 
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Figure 3.1.5 - Ability of the selective A2A receptor agonist, CGS 21680 (10 nM), and 
of the A2A receptor antagonist, SCH 58261 (50 nM), to modify the action of GDNF 
(10 ng/ml) on [
3
H]dopamine release in striatal slices in the presence of the GABAA 
and GABAB receptor antagonists, bicuculline (10 μM) and CGP 55845 (1 μM). Zero 
percent in the ordinates represents the S2/S1 ratio obtained in the absence of GDNF for 
each experimental condition indicated below the bars. Results are mean SEM from n 
experiments performed in duplicate.*p <0.05 as compared with 0% (Student's t test); φp 
<0.05 as compared with the effect of GDNF (10 ng/ml) in the absence of other drugs (left 
column) (one-way ANOVA analysis followed by Bonferroni's test). 
 
 
 
GDNF Effects Modulation by A2A Receptors in the Rat Striatum 
 
 96 
3.1.7. Discussion 
 
The present results first show that GDNF acutely increases 
evoked dopamine release in rat striatal slices and synaptosomes and, 
most importantly, that GDNF-induced enhancement of dopamine release 
is modulated by adenosine A2A receptors, which provides a first 
evidence for a crosstalk between adenosine A2A receptors and GDNF in 
the striatum. Intranigral injections of GDNF (Hebert and Gerhardt, 1997) 
or of an adenoviral vector encoding for GDNF (Smith et al., 2005) 
enhance striatal dopamine levels and dopamine release even in 6-
hydroxydopamine lesioned (Smith et al., 2005) or old (Hebert and 
Gerhardt, 1997) rats. Similar observations have been made in aged 
Rhesus monkeys after repeated injections of GDNF in the lateral 
ventricle (Grondin et al., 2003). GDNF has also been shown to increase 
cell body excitability of cultured midbrain neurons (Yang et al., 2001). 
Altogether, these evidences clearly show that GDNF enhances 
dopaminergic function by promoting maturation and function of 
nigrostriatal dopaminergic neurons, but do not demonstrate a direct 
action of GDNF at striatal nerve endings. The isolated striatum does not 
possess the cell bodies of dopaminergic neurons, which are located at 
the substantia nigra. Therefore, the now reported enhancement of 
dopamine release caused by GDNF acutely applied to striatal slices or 
striatal synaptosomes shows that this neurotrophic factor acts on 
dopaminergic nerve terminals, where it regulates dopamine release. 
GDNF may then have a dual role in nigrostriatal dopaminergic neurons 
to protect or even rescue dopaminergic nigrostriatal neuronal function: 
one at the cell bodies in the nigra, promoting their maturation and 
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sprouting, which secondarily leads to enhanced striatal dopamine levels 
and dopamine release, and another localized at striatal nerve endings, 
directly enhancing dopamine release. As is also shown, this direct 
GDNF action is under control of adenosine A2A receptors, most probably 
located presynaptically at dopaminergic nerve terminals, since the A2A 
receptors/GDNF crosstalk could be observed in isolated synaptosomes, 
where interactions at the circuit level are absent (see Raiteri and Raiteri, 
2000). Blockade of GABAergic transmission enhanced the evoked 
release of dopamine but reduced the effect of GDNF on dopamine 
release (compare Figures 3.1.4 and 3.1.5) suggesting that part but not 
all of the excitatory effect of GDNF on dopamine release depends upon 
GABAergic transmission. Interestingly, the magnitude of the 
enhancement of dopamine release caused by GDNF in synaptosomes, 
where a crosstalk between different neuronal structures might be 
virtually absent, was similar to that observed in slices upon inhibition of 
GABAergic transmission. Further studies are required to investigate how 
the functioning of GABAergic circuits in slices facilitates the effect of 
GDNF and whether this also occurs in vivo. The striatal GABAergic 
MSNs, which represent more than 90% of striatal neurons, receive 
intrastriatal GABAergic inputs from axon collaterals of the medium spiny 
neurons themselves and from GABAergic interneurons. Presynaptic 
inhibitory A2A receptors in the GABAergic interneurons relieve the 
inhibitory inputs to the spiny neurons, therefore enhancing its activity 
(Mori et al., 1996). Postsynaptic A2A receptors in the GABAergic output 
neurons inhibit D2 receptor functioning (see e.g. Ferré et al., 2003) and 
inhibit NMDA receptor functioning (Wirkner et al., 2004). It is possible 
that this multiplicity of A2A receptor mediated actions in striatal 
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GABAergic neurons contributes to the CGS 21680-induced inhibition of 
the effect of GDNF on dopamine release, since this inhibition (1) was 
observed in slices but not in synaptosomes; (2) was mimicked by 
inhibitors of GABAergic transmission and (3) was fully absent when 
GABAergic transmission was inhibited. The GABA-independent 
enhancement of dopamine release caused by GDNF in slices was 
facilitated by co-activation of adenosine A2A receptors, as it occurred in 
isolated nerve endings. Both in synaptosomes and in slices, either in the 
presence or in the absence of GABAergic transmission, the action of 
GDNF was prevented by A2A receptor antagonists, which allowed us to 
suggest that the facilitatory action of GDNF upon striatal dopamine 
release requires co-activation of adenosine A2A receptors. In contrast 
with what occurs in cholinergic and GABAergic striatal nerve endings 
(Kirk and Richardson, 1994), dopamine release from striatal nerve 
endings is not under control of adenosine A2A receptors (Jin et al., 1993; 
Lupica et al., 1990 and present results), which led to the concept that 
these receptors might be absent from striatal dopaminergic nerve 
endings. However, we clearly show that A2A receptors in striatal 
dopaminergic nerve terminals modulate the action of GDNF on 
dopamine release. Therefore, the role of A2A receptors in the 
dopaminergic nerve endings might be as modulators of the action of 
other presynaptic receptors, rather than exerting a direct modulation of 
dopamine release. This reinforces the idea (see Sebastião and Ribeiro, 
2000) that a main role of A2A receptors in different brain areas is to 
interact with receptors for other neuromodulators, a process probably 
involved in the fine tuning of neuronal function.  
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3.2. Adenosine A2A receptor modulation of the cortical-
induced protein phosphorylation in the striatum 
 
3.2.1. Rationale of the study 
 
Both enkephalinergic (D2- and A2A- regulated) and dynorphinergic 
(D1- and A1- regulated) neurons receive corticostriatal afferents and 
display excitatory postsynaptic responses to corticostriatal stimulation 
(Kawaguchi et al., 1990), but corticostriatal stimulation selectively 
activates MAPK and immediate early gene (IEG) expression in the 
enkephalinergic neurons without activation in dynorphinergic neurons 
(Berretta et al., 1997; Gerfen et al., 2002). A2A receptor-mediated PKA 
activation can potentially phosphorylate different substrates (for instance 
GluR1 subunit of the AMPA receptor at Ser845 and ERK1/2) involved in 
synaptic plasticity (see Introduction, section 1.3.3). However, under 
basal conditions, these PKA-dependent changes are impaired due to the 
tonic activation operated by dopamine D2 receptors (for review, see 
Ferré et al., 2004, 2005). Since stimulation of A2A (and mGlu5) receptors 
inhibits dopamine binding to D2 receptors and activates MAPK (Popoli et 
al., 2001; Ferré et al., 2002; Nishi et al., 2003), in the present work it was 
assessed if a strong cortical glutamatergic input induced by electrical 
stimulation would allow sufficient stimulation of A2A receptors (by 
adenosine co-released with glutamate), overriding the tonic inhibition 
operated by dopamine D2 receptors upon the phosphorylation of GluR1 
and ERK1/2 proteins in the striatum. 
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3.2.2. Adenosine A2A receptor effect upon cortical stimulation-
induced protein phosphorylation 
 
3.2.2.1 Adenosine A2A receptor effect upon cortical stimulation-
induced ERK1/2 phosphorylation 
 
As reported previously (Sgambato et al., 1998; Gerfen et al., 
2002), cortical stimulation in the orofacial area of the lateral agranular 
motor cortex (demonstrated by the selective elicitation of jaw 
movements) induced a predominant phosphorylation of ERK1/2 in the 
lateral caudate-putamen at the AP level of bregma 0.01.0 mm (Figures 
3.2.1, 3.2.2A,B). Western blot assays were therefore performed from 
punches of the lateral striatum corresponding to the area with maximal 
ERK1/2 phosphorylation.  
Cortical stimulation induced a significant increase in ERK1/2 
phosphorylation in the ipsilateral striatum (14512.1%, n=10) compared 
with electrode-implanted nonstimulated controls (1012.3%, n=10) 
(Figure 3.2.2A,B). This effect was significantly counteracted by the 
selective A2A receptor antagonist MSX-3 (3 mg/kg) (1068.1%, n=10) 
(Figure 3.2.2A,C), and by the nonselective adenosine receptor 
antagonist caffeine (10 mg/kg) (8317.2%, n=6) (Figure 3.2.2A,D), but 
not by the A1 receptor antagonist CPT (4.8 mg/kg) (14317.9%, n=6) 
(Figure 3.2.2A,E). None of the adenosine receptor ligands produced any 
significant effect in sham non-stimulated animals. There were not 
significant differences in the values of total ERK1/2 between the different 
sham and stimulated groups (Figure 3.2.2A). 
In these in vivo experiments the A2A receptor antagonist, MSX-3, 
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was used instead of SCH 58261, which was used in vitro. This was 
because SCH 58261 (but not MSX-3) was previously characterized in 
the same in vitro conditions and MSX-3 (but not SCH 58261) in the 
same in vivo conditions as those used in this study. Both compounds 
have demonstrated their selectivity for A2A receptors at the concentration 
(SCH 58261, 50 nM) and dose (MSX-3, 3 mg/kg i.p.) now used, as 
shown before (Karcz-Kubicha et al., 2003; Ciruela et al., 2006). 
 
3.2.2.2. Adenosine A2A receptor effect upon cortical stimulation-
induced AMPA receptor phosphorylation 
 
Corticostriatal stimulation was also found to significantly increase 
phosphorylation of the Ser845 residue of the GluR1 subunit of the AMPA 
receptor in the ipsilateral striatum (18013.5%, n=11) as compared with 
control, non-stimulated animals (1006.7%, n=13) (Figure 3.2.3A,B).  
Striatal AMPA receptor phosphorylation was also completely 
counteracted by MSX-3 (3 mg/kg) (1046.6%, n=9) or caffeine (10 
mg/kg) (7310.3%, n= 5) (Figure 3.2.3A,C,D), whereas CPT (4.8 mg/kg) 
(Figure 3.2.3A,E) did not significantly modify AMPA receptor 
phosphorylation induced by cortical stimulation (1444.6%, n=7). Again, 
none of the adenosine receptor ligands produced any significant effect in 
sham non-stimulated animals. There were not significant differences in 
the values of total GluR1 subunit of the AMPA receptors between the 
sham and stimulated groups (Figure 3.2.3A). 
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Figure 3.2.1 - Immunohistochemical localization of striatal ERK1/2 
phosphorylation induced by cortical electrical stimulation. A,D. 
Immunohistochemical localization of phosphorylated ERK1/2 in coronal sections (AP 
level of bregma 0.0) through the striatum ipsilateral to the implanted electrode from 
stimulated (A) and sham nonstimulated (D) animals. B, C, E, F. Higher magnification of 
the respective fields indicated in A and D, which shows cells displaying immunoreactivity 
to phospho-ERK1/2 antibody in the lateral caudate-putamen of the stimulated animals. 
Scale bars, 250m. 
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Figure 3.2.2 - Striatal ERK1/2 phosphorylation induced by cortical electrical 
stimulation. A. Representative Western blots. B. ERK1/2 phosphorylation induced by 
cortical electrical stimulation. C,D. A2A receptor antagonists, MSX-3 (C) and caffeine (D) 
counteracted ERK1/2 phosphorylation induced by cortical stimulation. E. A1 receptor 
antagonist, CPT, does not counteract ERK1/2 phosphorylation induced by cortical 
stimulation. Results are shown in meansSEM (n = 6-10 per group) of representative 
Western blots.  p<0.05, significantly different compared with vehicle-treated non 
stimulated group (ANOVA with Tukey-Kramer tests). *p<0.05, significantly different 
compared with vehicle-treated stimulated group (ANOVA with Tukey-Kramer tests). 
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Figure 3.2.3 - Striatal GluR1 phosphorylation induced by cortical electrical 
stimulation. A. Representative Western blots. B. GluR1 phosphorylation induced by 
cortical electrical stimulation. C,D. A2A receptor antagonists, MSX-3 (C) and caffeine (D) 
counteracted GluR1 phosphorylation induced by cortical stimulation. E. A1 receptor 
antagonist CPT does not counteract GluR1 phosphorylation induced by cortical 
stimulation. Results are shown in meansSEM (n = 5-13 per group) of representative 
Western blots.  p<0.05, significantly different compared with vehicle-treated non 
stimulated group (ANOVA with Tukey–Kramer tests). *p<0.05, significantly different 
compared with vehicle-treated stimulated group (ANOVA with Tukey–Kramer tests). 
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3.2.3. Discussion 
 
In the striatum, there are two major types of glutamatergic 
synapses, the D1 receptor-regulated and the D2 (and A2A) receptor-
regulated glutamatergic synapses, mostly localized at the heads of the 
dendritic spines of the GABAergic dynorphinergic and enkephalinergic 
neurons, respectively (Ferré et al., 2005). In the GABAergic 
dynorphinergic neuron, D1 receptor stimulation modulates neuronal 
excitability and glutamatergic neurotransmission by inducing PKA-
mediated phosphorylation of different substrates. These substrates 
include ERK1/2 and Ser845 of the GluR1 subunit of the AMPA receptor 
(Wolf et al., 2003), both critical steps in the establishment of plastic 
changes in excitatory synapses, involving recruitment of AMPA 
receptors to the postsynaptic density (Malinow and Malenka, 2002; Lee 
et al., 2003; Thomas and Huganir, 2004). As mentioned above (see 
rationale and 1.3.3), D1 receptor-mediated mechanisms by which 
dopamine can potentiate the function and plasticity of glutamatergic 
synapses in the GABAergic dynorphinergic neuron is operated by 
adenosine activating A2A receptors. At the postsynaptic site, A2A 
receptors form heteromeric complexes with D2 and metabotropic 
glutamate mGlu5 receptors (Ferré et al., 2005) and costimulation of A2A 
and mGlu5 receptors exerts a synergistic effect on their ability to inhibit 
dopamine binding to the D2 receptor and on MAPK activation (Popoli et 
al., 2001; Ferré et al., 2002; Nishi et al., 2003). In the present work it 
was postulated that a strong cortico-limbic-thalamic glutamatergic input 
would produce a sufficient amount of intrasynaptic glutamate and 
adenosine (most probably derived from ATP co-released with 
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glutamate), with a significant stimulation of postsynaptic A2A receptors. 
Then, under conditions of strong glutamatergic input, adenosine and A2A 
receptors can provide a mechanism of facilitation of plastic changes in 
the excitatory synapses of the GABAergic enkephalinergic neurons 
(Ferré et al., 2005). The present results strongly support this hypothesis, 
because phosphorylation of ERK1/2 and GluR1 at Ser845 induced by 
stimulation of corticostriatal afferents was completely dependent on A2A 
receptor function.  
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3.3. Adenosine A2A receptor modulation of GDNF effects on 
the glutamatergic corticostriatal pathway  
 
3.3.1. Rationale of the study  
 
In accordance with its ability to bolster nigrostriatal innervation, 
GDNF affords neuroprotection in Parkinson‟s disease. As mentioned in 
3.1, GDNF facilitates dopamine release in a manner dependent on 
adenosine A2A receptor activation. GDNF also affords beneficial effects 
in animal models of Huntington‟s disease (reviewed in Alberch et al., 
2004), where the control of the viability of dopaminergic neurons is not 
considered a prominent etiological factor. Dysfunction of the 
glutamatergic system may be a general feature of neurodegenerative 
diseases (Lipton and Rosenberg, 1994) and, accordingly, is present in 
Parkinson‟s disease (Day et al., 2006) as well as Huntington´s disease 
(Cepeda et al., 2007). GDNF protects several types of neurons against 
glutamate-induced toxicity in different brain areas (Yoo et al., 2006; 
Wong et al., 2005) and it was observed an up-regulation of GDNF and 
its receptors after excitotoxic insults to the striatum (Alberch et al., 
2002). Thus, the trophic factor has been suggested as a potential 
therapeutic approach in neurodegenerative conditions secondary to 
excitotoxic-induced damage (Araújo et al., 1997; Perez-Navarro et al., 
1996; 1999).  
These observations lead to the hypothesis that GDNF may act 
through broader mechanism of action to preserve striatal circuits from 
injury, which might also involve the control of glutamatergic inputs, a 
hypothesis that has not yet been experimentally tested. Thus, in the 
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present work, it was tested if GDNF controlled the corticostriatal 
glutamatergic pathway in an A2A receptor-dependent manner, as it 
occurred with the dopaminergic influx to the striatum.  
 
3.3.2. GDNF control of the glutamatergic input to the striatum 
 
3.3.2.1. GDNF facilitates K+-evoked glutamate release from striatal 
synaptosomes 
 
In striatal synaptosomes incubated with [3H]glutamate, the initial 
(first three collected samples) basal release of tritium was 2.72±0.05% of 
the total tritium incorporated in the synaptosomes (fractional release) 
(n=6) (Figure 3.3.1). The first stimulation period (S1) caused a near 1.5 
fold increase in the amount of tritium release; the second stimulation 
period (S2) caused a slightly smaller increase in tritium release than the 
first one, so the S2/S1 ratio obtained was 0.91±0.05 (n=6). To evaluate 
the action of GDNF upon glutamate release from synaptosomes, we 
used a concentration of GDNF (10 ng/ml) known to facilitate dopamine 
release from the same preparation (see 3.1.2 and also Gomes et al., 
2006) as well as to increase dopamine levels and number of 
dopaminergic neurons in culture (Schatz et al., 1999). 
When GDNF (10 ng/ml) was present during S2, the S2/S1 ratio 
was increased to 1.1±0.08 (p<0.05 as compared with absence of GDNF 
in the same synaptosomal batch), corresponding to a 13.1±2.8% (n=5, 
p<0.05) enhancement of [3H]glutamate release (Figure 3.3.2). 
 
 
Results 
 
 109 
3.3.2.2. GDNF-mediated enhancement of K+-evoked glutamate 
release depends on A2A receptor activation 
 
As illustrated in Figure 3.3.2, the GDNF-induced enhancement of 
glutamate release was abolished (p<0.05, n=3) when the A2A receptor 
antagonist was present. In two of these experiments the effect of GDNF 
in the absence of SCH 58261 was also tested in the same synaptosomal 
batch and the usual excitatory effect of GDNF (10 ng/ml) was observed. 
The abolishment of the effect of GDNF by the A2A receptor antagonist 
suggests that the effect of GDNF in striatal glutamatergic nerve endings 
requires tonic activation of adenosine A2A receptors. In the presence of 
CGS 21680, GDNF caused a marked increase in the S2/S1 ratio (Figure 
3.3.2), corresponding to a facilitatory effect of 29±6.9% (n=3). This effect 
of GDNF was significantly (p<0.05) greater than that observed in the 
absence of CGS 21680; the potentiation of the GDNF effect by CGS 
21680 should be attributed to A2A receptor activation, since it was 
prevented by the selective (Zocchi et al., 1996) A2A receptor antagonist 
SCH 58261 (50 nM; Figure 3.3.2). The presence of CGS 21680 (10 nM) 
or SCH 58261 (50 nM) during S1 and S2 did not significantly modify the 
S2/S1 ratio (p>0.05). The amount of tritium released during S1 in the 
absence of any drug or in the presence of CGS 21680 (10 nM) or SCH 
58261 (50 nM) was also not significantly different (p>0.05). 
 
 
 
 
 
GDNF Effects Modulation by A2A Receptors in the Rat Striatum 
 
 110 
 
 
 
 
0 3 6 9 12 15 18
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
GDNF, 10 ng/ml
S2
S1 S2
CGS 21680 (10 nM)
S1, S2
Time (min)
F
ra
c
ti
o
n
a
l 
R
e
le
a
s
e
 (
%
)
 
 
 
Figure 3.3.1 - GDNF enhances electrically evoked [
3
H]glutamate release from 
striatal synaptosomes. Averaged time course of [
3
H]glutamate release experiments. 
Striatal synaptosomes were labelled with [
3
H]glutamate as described in Experimental 
Procedures. Release was evoked twice (S1 and S2) by chemical stimulation (20 mM KCl, 
30 sec), as indicated by the bars above the abscissa. CGS 21680 (10 nM) was added 15 
min before S1 onwards, and was present throughout all the experiment in both control 
and test conditions (indicated by the upper horizontal bar). GDNF was added to the test 
chambers 2 min before S2, as indicated by the upper horizontal bar (filled circles), 
whereas it was not added to the parallel control chambers (open circles). Each point 
represents the mean±SEM of the results obtained in 4-5 experiments performed in 
duplicate.  
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Figure 3.3.2 - Blockade of the effect of GDNF by the A2A receptor antagonist, SCH 
58261, and its potentiation by the A2A receptor agonist, CGS 21680. The effect of 
GDNF on the evoked release of glutamate was estimated by changes in the amount of 
[
3
H]glutamate release in S2 as referred to S1 (S2/S1 ratio). 0% represents the S2/S1 ratio 
in the absence of GDNF. Results are mean±SEM from 3-5 experiments performed in 
duplicate. *p<0.05 as compared with the effect of GDNF in the absence of other drugs 
(left column) (one-way ANOVA analysis followed by Bonferroni's test); 'p<0.05 as 
compared with the effect of GDNF in the presence of CGS 21680 (third column from left) 
(one-way ANOVA analysis followed by Bonferroni's test). The amount of tritium released 
during S1 under the different conditions was not significantly different (p>0.05, one-way 
ANOVA analysis followed by Bonferroni's test); the presence of CGS 21680 or SCH 
58268 also did not significantly affect the S2/S1 ratio (p>0.05, one-way ANOVA analysis 
followed by Bonferroni's test). 
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3.3.3. In vivo A2A receptor modulation of the activation state of 
GDNF receptor upon cortical stimulation 
 
3.3.3.1. Cortical stimulation induces GDNF receptor 
phosphorylation in the striatum 
 
Cortical stimulation in the orofacial area of the lateral agranular 
motor cortex induced an increase (1367.3%, n=8) in Ret 
phosphorylation in the ipsilateral striatum compared to electrode-
implanted non-stimulated controls (1007.8%, n=6) (Figure 3.3.5A,B). 
Total Ret levels were not significantly affected by cortical stimulation in 
any group of animals (Figure 3.3.5A). 
 
3.3.3.2. Cortical stimulation-induced phosphorylation of GDNF 
receptor in the striatum requires A2A receptor tonic activation 
 
The dependency on A2A receptor activation was evaluated in a 
parallel group of animals where cortical stimulation was performed after 
administration of a selective A2A receptor antagonist, MSX-3 (3 mg/kg, 
i.p.) or after the administration of a selective A1 receptor antagonist, CPT 
(4.8 mg/kg, i.p.). The dose of the adenosine antagonists was previously 
shown to provide motor activation by selectively antagonizing A1 
receptors (CPT) or A2A receptors (MSX-3) (Karcz-Kubicha et al., 2003). 
In animals under MSX-3, cortical stimulation failed to induce Ret 
phosphorylation (1216.1%, n=8) (Figure 3.3.4A,C). In contrast, 
previous systemic administration of the A1 receptor antagonist CPT did 
not counteract the influence of cortical stimulation upon Ret 
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phosphorylation (13710.2%, n=7) (Figure 3.3.5A,D). As shown in 
Figures 3.3.3A, total Ret levels were not significantly affected by cortical 
stimulation in any group of animals.  
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Figure 3.3.3 - Striatal phosphorylation of the GDNF receptor component Ret is 
induced by cortical electrical stimulation and depends on A2A receptor activation.  
A. Representative Western blots. B. Ret phosphorylation induced by cortical electrical 
stimulation. C. A2A receptor antagonist, MSX-3 counteracted Ret phosphorylation 
induced by cortical stimulation. D. A1 receptor antagonist CPT does not counteract Ret 
phosphorylation induced by cortical stimulation. Results are shown in meansSEM (n = 
6-8 per group) of representative Western blots.  p<0.05, significantly different compared 
with vehicle-treated non stimulated group (ANOVA with Tukey–Kramer tests). *p<0.05, 
significantly different compared with vehicle-treated stimulated group (ANOVA with 
Tukey–Kramer tests). 
GDNF Effects Modulation by A2A Receptors in the Rat Striatum 
 
 114 
3.3.4. Discussion 
 
The present findings provide the first demonstration of the ability 
of GDNF to directly enhance glutamate release dependently on the co-
activation of A2A receptors. It was recently shown by using hippocampal 
preparations (Koeberle et al., 2008) that GDNF exerts an anti-apoptotic 
effect by up-regulating glutamate transporters in the CNS and it acutely 
modulates synaptic transmission in the midbrain dopaminergic neurons, 
which co-release dopamine and glutamate (Bourque and Trudeau, 2000; 
Wang et al., 2003). However, a direct evaluation of the actions of GDNF 
upon striatal glutamate release has not been performed so far. 
It is usually conceived that the beneficial effects of GDNF in 
Parkinson´s disease result from its protective and/or restorative effects 
acting as a growth factor on nigrostriatal dopaminergic neurons 
(reviewed in Hurelbrink and Barker, 2004), but GDNF also exerts 
beneficial effects in animal models of Huntington‟s disease (reviewed in 
Alberch et al., 2004), where the control of the viability of dopaminergic 
neurons is not considered a prominent etiological factor. Furthermore, 
there is increasing evidence that neurodegeneration begins with a 
synaptic dysfunction which later evolves into an overt damage of 
neurons through a dying back mechanism (Coleman and Perry, 2002; 
Wishart et al., 2006). This has been documented in either Parkinson‟s 
(reviewed in Dauer and Przedborski, 2003) or Huntington‟s disease (Li 
et al., 2001; 2003) and suggests that the beneficial role of GDNF in 
different neurodegenerative diseases affecting striatal circuits can also 
be adequately explained by considering its direct effects within the 
striatum and, according to the present data, in glutamatergic terminals. 
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Another important conclusion from this study is the re-inforcement of the 
importance of adenosine A2A receptors in the control of the effects 
operated by GDNF. In fact, it was now observed that GDNF causes a 
minor effect on the release of glutamate, which was enabled upon 
activation of A2A receptors. Presynaptic A2A receptors localized in 
glutamatergic nerve terminals have been recently demonstrated to exert 
an important modulatory role of striatal glutamate release (Ciruela et al., 
2006). The main source of adenosine that activates these presynaptic 
A2A receptors seems to be ATP which is co-released with glutamate 
(Ferré et al., 2005). As pointed out in the Introduction (see 1.3.3.), A2A 
receptors localized in glutamatergic nerve terminals form heteromers 
with A1 receptors and function as a concentration-dependent switch, by 
which low concentrations of adenosine (by acting at A1 receptors) inhibit 
glutamate release and high concentrations of adenosine (by acting at 
A2A receptors, which shuts down A1 receptor signalling), facilitate 
glutamate release (Ferré et al., 2007). The present results indicate that 
GDNF may provide an additional key component for the operation of the 
A1-A2A receptor heteromer.  
The in vitro approaches were also extended to in vivo studies 
further supporting the pivotal role of A2A receptors to enable the 
functioning of the modulation system operated by GDNF. It was 
observed that cortical stimulation of the orofacial area of the lateral 
agranular motor cortex increases Ret phosphorylation in the ipsilateral 
striatum, which indicates that stimulation of cortical afferents promotes 
activation of the effector of the GDNF receptor in the striatum. 
Accordingly, GDNF protects several types of neurons against glutamate-
induced toxicity in different brain areas (Yoo et al., 2006; Wong et al., 
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2005) and it was observed an up-regulation of GDNF and its receptors 
after excitotoxic insults to the striatum (Alberch et al., 2002). The cortical 
stimulation-induced of Ret phosphorylation requires co-activation of A2A 
receptors, further suggesting that GDNF actions in the striatum are 
seriously impaired when A2A receptors are not free to be activated by its 
endogenous ligand. As described in the previous section (see 3.2 and 
also Quiroz-Molina et al., 2006), under conditions of a strong cortico-
limbic-thalamic input, the electrical stimulation-induced phosphorylation 
of different substrates implicated in plasticity (such as ERK1/2) is 
dependent upon A2A receptor activation and it is important to notice that 
GDNF also has the ability to enhance the phosphorylation of ERK1/2 
(Kobori et al., 2004; Salvatore et al., 2004; Yang et al., 2001). 
Altogether, these observations suggest that GDNF, dependently on A2AR 
activation, controls glutamatergic inputs to the striatum and, on the other 
hand, may be recruited as a defensive response to glutamate 
excitotoxicity and/or possibly involved in plastic changes in the striatum.  
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3.4. GDNF receptor components distribution in the rat striatum, 
cellular and subsynaptic localization and co-localization with A2A 
receptor 
 
3.4.1. Rationale of the study 
 
The striatum is a complex network of neuronal circuits, which are 
triggered by glutamatergic afferents, are mainly GABAergic in nature 
and are modulated by a main external dopaminergic nigrostriatal input 
(Gerfen, 2004). There are also cholinergic interneurons and GABAergic 
neurons (Tepper and Bolam, 2004). To understand the role of the GDNF 
presynaptic modulation system, it is important to determine which 
type(s) of nerve terminals are equipped with the GDNF receptor system. 
In spite of some studies on the regional and cellular distribution of GDNF 
receptor components at the mRNA expression level (Wang et al., 2008; 
Cho et al., 2004; Sarabi et al., 2003; Widenfalk et al., 1997; Nosrat et al., 
1997; Trupp et al., 1997), a systematic analysis of GDNF receptor 
distribution among different striatal nerve terminals at the protein level 
has not yet been reported so far. The distribution of GDNF receptors in 
several neuronal populations in the striatum was therefore analysed in 
order to further support a physiological role of GDNF upon 
neurotransmitter release.  
Presynaptic modulation systems can either directly control 
release of neurotransmitters or indirectly modify it through the control of 
the metabolism and/or viability of synaptic contacts. The former are 
expected to be located in the active zone (i.e. where neurotransmitter 
release takes place), where the later are not required to display such a 
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confined localization. To gauge the possible relevance of the GDNF 
receptor system as a modulator of neurotransmitter release, I next 
investigated the cellular and sub-synaptic localization of Ret and GFR1, 
in particular their localization in the active zone. Finally, it seemed of 
particular importance to evaluate if GDNF receptor components co-
localize with adenosine A2A receptors at the cellular level, particularly at 
glutamatergic and dopaminergic terminals, where a functional interplay 
between GDNF and A2A receptors was observed. 
 
3.4.2. GDNF receptor proteins are located in striatal nerve terminals 
 
As illustrated in Figure 3.4.1, both Ret (Figures 3.4.1A,B) and 
GFR1 (Figures 3.4.1A,C) immunoreactivity were present in 
synaptosomal membranes with a density similar to that found in total 
membranes from the whole striatum.  
Both proteins were present in the active zone (Figure 3.4.2A). 
Thus, when quantifying the relative density of Ret and GFR1 
immunoreactivity in the three sub-synaptic fractions (presynaptic active 
zone, postsynaptic density and extra-synaptic fractions) in three different 
assays from different groups of rats, it was found that Ret and GFR1 
immunoreactivity is mainly located in the presynaptic active zone fraction 
(34±5.5% and 35±7.3% of total immunoreactivity, n=5) and in the 
postsynaptic density (50±3.0% and 52±8.9% of total immunoreactivity, 
n=5) and has a significantly (p<0.05) lower relative abundance in the 
extrasynaptic fraction of nerve terminals (17±3.4% and 12±3.1% of total 
immunoreactivity, n=5) (Figures 3.4.2B,C). 
The next step was to estimate if the proteins constituting the 
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GDNF receptor were confined to a reduced number of nerve terminals or 
if most nerve terminals in the striatum were equipped with this 
modulation system. For that purpose, a double immunocytochemical 
labelling of Ret or GFR1 was carried out with a marker of nerve 
terminals, synaptophysin, a protein located in synaptic vesicles. As 
illustrated in Figure 3.4.3A, there was a co-localization of synaptophysin 
with either Ret or GFR1. Thus, 56±2.3% (n=3) of the general population 
of striatal nerve terminals, identified as synaptophysin immunopositive 
elements were also endowed with Ret receptor component and 61±1.2% 
(n=4) of the referred elements are equipped with GFR1 component of 
the receptor (Figure 3.4.3B). Therefore, a high proportion of the nerve 
endings at the striatum possess GDNF receptor complex. 
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Figure 3.4.1 - GDNF receptor proteins (Ret and GFRα1) are present in 
synaptosomal membranes with a similar density to that found in total membranes 
from the whole striatum. A. Representative Western blots showing that both Ret and 
GFRα1 immunoreactivity is located in membranes from purified nerve terminals with a 
density similar to that found in total striatal membranes. B. Quantification of the 
immunoreactivity of Ret (panel A). C. Quantification of the immunoreactivity of GFR1 
(panel A). Results are shown in mean±SEM of 4 experiments.  
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Figure 3.4.2 - GDNF receptor proteins (cRet and GFRα1) are located in synapses, 
namely in the presynaptic active zone of striatal nerve terminals. A. Representative 
Western blots showing that Ret and GFRα1 immunoreactivity is mainly located in the 
presynaptic active zone and in the postsynaptic density, as evaluated upon subsynaptic 
fractionation of purified striatal nerve terminals into the presynaptic active zone (enriched 
in SNAP25), postsynaptic density (enriched in PSD95) and extra-synaptic fraction 
(enriched in synaptophysin); the last lane (SF) shows immunoreactivity in the 
synaptosomal fraction before subsynaptic fractionation. B. Quantification of the 
immunoreactivity of Ret (panel A). C. Quantification of the immunoreactivity of GFR1 
(panel A). Results are shown in mean±SEM of 5 experiments.  
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Figure 3.4.3 - Ret and GFRα1 are located in more than half of striatal nerve 
terminals. A. Representative double labelling immunocytochemical co-localization of the 
Ret and GFRα1 immunoreactivity with synaptophysin in striatal nerve terminals. As 
shown in B., more than half of striatal nerve terminals (synaptophysin-immunopositive) 
were endowed with Ret and GFRα1 immunoreactivity (mean±SEM of 3-4 experiments). 
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3.4.3. Mapping GDNF receptor components in different types of 
striatal nerve terminals 
 
Double immunocytochemical studies were carried out looking at 
the co-localization of Ret or of GFR1 immunoreactivity with markers of 
the different types of nerve terminals. As shown in Figures 3.4.4A and 
3.4.5A, only few GABAergic terminals (immunopositive for vesicular 
GABA transporters) were endowed with Ret (18±2.5%, Figure 3.4.4B) or 
GFR1 (21±1.2%, Figure 3.4.5B) immunoreactivity (n=4). The 
percentage of cholinergic terminals (immunopositive for vesicular 
acetylcholine transporters) equipped with at least one of the GDNF 
receptor components is even lower (Ret: 4.7±2.7%; GFR1: 5.3±3.1%, 
n=4, Figures 3.4.4B and 3.4.5B). In contrast, numerous dopaminergic 
terminals (immunopositive for tyrosine hydroxylase) were 
immunopositive for GDNF receptor proteins (Ret: 61±1.6%; GFR1: 
56±0.3%, n=3-4, Figures 3.4.4B and 3.4.5B). Likewise, a large 
percentage of striatal glutamatergic terminals (immunopositive for 
vesicular glutamate transporters 1 and 2) were immunopositive for 
GDNF receptor components (Ret: 45±2.4%; GFR1: 53±0.9%, n=3-4, 
Figures 3.4.4B and 3.4.5B).  
 
 
 
 
 
 
 
GDNF Effects Modulation by A2A Receptors in the Rat Striatum 
 
 124 
 
 
vG
LU
T1
/2
  
0
10
20
30
40
50
60
70
TH
  v
G
A
T
  
vA
C
hT
%
 c
o
-l
o
c
a
li
z
a
ti
o
n
 R
e
t 
im
m
u
n
o
re
a
c
ti
v
it
y
A.
B.
Ret
vGluT1/2
vGAT
vAChT
TH
MergedNerve terminal
%
 c
o
-l
o
c
a
li
z
a
ti
o
n
 R
e
t 
im
m
u
n
o
re
a
c
ti
v
it
y
 
 
 
Figure 3.4.4 - Ret protein is mainly located in dopaminergic and glutamatergic, 
rather than GABAergic and cholinergic nerve terminals in the rat striatum. A. 
Representative double labelling immunocytochemical co-localization of Ret and different 
markers of different types of nerve terminals, namely tyrosine hydroxylase (TH, marker 
of dopaminergic neurons, first row), vesicular glutamate transporters types 1 and 2 
(vGluT1/2, markers of glutamatergic terminals, second row), vesicular GABA transporter 
(vGAT, marker of GABAergic terminals, third row) and vesicular acetylcholine transporter 
(vAChT, marker of cholinergic terminals, last row). B. Average number of each type of 
terminals endowed with Ret, showing that this protein constituting the GDNF receptor is 
more abundantly located in dopaminergic and glutamatergic terminals of the rat striatum. 
The results are mean±SEM of 3-4 experiments. 
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Figure 3.4.5 - GFR1 protein is mainly located in dopaminergic and glutamatergic, 
rather than GABAergic and cholinergic nerve terminals in the rat striatum. A. 
Representative double labelling immunocytochemical co-localization of GFR1 and 
different markers of different types of nerve terminals, namely tyrosine hydroxylase (TH, 
marker of dopaminergic neurons, first row), vesicular glutamate transporters types 1 and 
2 (vGluT1/2, markers of glutamatergic terminals, second row), vesicular GABA 
transporter (vGAT, marker of GABAergic terminals, third row) and vesicular acetylcholine 
transporter (vAChT, marker of cholinergic terminals, last row). B. Average number of 
each type of terminals endowed with GFR1, showing that this protein constituting the 
GDNF receptor is more abundantly located in dopaminergic and glutamatergic terminals 
of the rat striatum. The results are mean±SEM of 3-4 experiments. 
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3.4.4. GDNF and adenosine A2A receptor are co-located in striatal 
glutamatergic and dopaminergic nerve terminals 
 
The tight control by A2A receptors of the effects of GDNF in both 
glutamatergic and dopaminergic terminals should require that both 
receptor systems should be located in a subset of both glutamatergic 
and dopaminergic terminals. Triple immunocytochemical analysis of the 
GDNF receptor proteins (Ret and GFR1), A2A receptors and markers of 
either glutamatergic (vGluT1/2) or dopaminergic (TH) terminals were 
therefore performed.  
As illustrated in Figure 3.4.6A,B, 13±0.9% (n=3) of the vGluT1/2-
positive striatal nerve terminals are simultaneously equipped with both 
A2A and Ret receptor and 9.4±1.6% (n=3) of the vGluT1/2 positive nerve 
terminals are equipped with both A2A and GFR1 receptor. Likewise, we 
also found that 12±1.0% (n=3) of the TH-positive nerve terminals are 
equipped with both A2A and Ret receptor and that 11±0.4% (n=3) of the 
TH-positive nerve terminals are equipped with both A2A and GFR1 
receptor (Figure 3.4.7A,B).  
Since the localization of A2A receptors in dopaminergic terminals 
is frequently questioned (e.g. Svenningsson et al., 1999), a confirmatory 
double immunocytochemical study was carried out using striatal 
synaptosomes to assess the presence of A2A receptor in striatal 
dopaminergic nerve terminals [labelled with TH or DAT (dopamine 
transporter) immunoreactivity]. We found that 21±4.3% (n=6) of the TH-
immunopositive striatal nerve terminals were endowed with A2A receptor 
immunoreactivity and 22±1.1% (n=5) of the DAT-immunopositive striatal 
nerve terminals were endowed with A2A receptor immunoreactivity 
Results 
 
 127 
(Figure 3.4.8). This constitutes the first direct demonstration for the 
presence of A2A receptors in dopaminergic terminals in the striatum, 
reinforcing previous functional data showing that A2A receptors enable 
GDNF actions in striatal dopaminergic nerve endings (see also Gomes 
et al., 2006). 
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Figure 3.4.6 - GDNF receptor proteins (Ret and GFRα1) are co-located with 
adenosine A2A receptors in glutamatergic nerve terminals of the rat striatum. A. 
Representative triple labelling immunocytochemical co-localization of adenosine A2A 
receptors and either Ret (upper row) or GFRα1 (lower row) in glutamatergic nerve 
terminals (immunopositive for vesicular glutamate transporters types 1 and 2, vGluT1/2), 
which is quantified in panel B. Average number of glutamatergic  terminals endowed with 
either A2AR and Ret/GFR1 (mean±SEM of 3 experiments). 
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Figure 3.4.7 - GDNF receptor protein (Ret and GFRα1) are co-located with 
adenosine A2A receptors in dopaminergic nerve terminals of the rat striatum. A. 
Representative triple labelling immunocytochemical co-localization of adenosine A2A 
receptors and either Ret (upper row) or GFRα1 (lower row) in dopaminergic nerve 
terminals (immunopositive for tyrosine hydroxylase, TH), which is quantified in panel B. 
Average number of dopainergic  terminals endowed with either A2AR and Ret/GFR1 
(mean±SEM of 3 experiments).  
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Figure 3.4.8 - Adenosine A2A receptors are localized at striatal dopaminergic nerve 
terminals. A. Representative double labelling immunocytochemical co-localization of 
adenosine A2A receptors in dopaminergic terminals, labelled either with tyrosine 
hydroxylase (TH, upper row) or dopamine transporters (DAT, lower row).  B. Average 
number of each type of TH- or DAT-immunopositive terminals endowed with A2A 
receptors (mean±SEM of 5-6 experiments). 
 
 
 
GDNF Effects Modulation by A2A Receptors in the Rat Striatum 
 
 130 
3.4.5. Discussion 
 
The present results provide direct morphological evidence 
indicating that adenosine A2A receptors co-locate with Ret and GFR1, 
GDNF receptor components, in a subset of dopaminergic and 
glutamatergic terminals of the rat striatum. Indeed, there was a co-
localization of A2A receptors and Ret/GFR1 immunoractivity in striatal 
nerve terminals and, in particular, in nerve terminals endowed with the 
tyrosine hydroxylase (TH) and with the vesicular glutamate transporters 
type1 and type 2 (vGlut 1/2), that is, dopaminergic and glutamatergic 
nerve terminals. These observations are consistent with the ability of 
GDNF to presynaptically enhance the release of dopamine (see 3.2. and 
also Gomes et al., 2006) and glutamate (see 3.3. and also Gomes et al., 
2009) from striatal nerve endings, upon the control of adenosine A2A 
receptors.  
The main question arising from these observations relates to the 
subcellular distribution of A2A receptors in the striatum. Indeed, the 
majority of these receptors is located outside nerve terminals in striatal 
tissue, namely in the postsynaptic density (Hettinger et al., 2001), where 
they exert their main striatal function, the control of the responsiveness 
of MSNs. It should be emphasised that these results are not in 
opposition to the well-defined postsynaptic role for adenosine in this 
brain area. Instead, they suggest a complementary role for A2A receptors 
at the presynaptic site, where they interact with receptors for 
neurotransmitters or trophic factors, in a strategic position to modulate 
synaptic functioning. Previous studies by others (Rodrigues et al., 2005; 
Ciruela et al., 2006) have documented the presence of adenosine A2A 
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receptors at the striatal glutamatergic terminal. At these terminals, the 
authors report the functional interaction between A2A receptors and 
glutamate metabotropic group 5 receptors (Rodrigues et al., 2005) or A1 
receptors (Ciruela et al., 2006) in the control of neurotransmitter release, 
which is consistent with the existence of receptor heteromers (Ferré et 
al., 2005; Ciruela et al., 2006). If evidence exists documenting the 
presence of A2A receptors at the glutamatergic terminal, their presence 
at the dopaminergic terminals of the striatum was still a matter of debate 
before the present work. As stated above (see 3.1.7), adenosine does 
not control striatal dopamine release via A2A receptors receptors (Jin et 
al., 1993; Lupica et al., 1990 and present results, see 3.1.2) and this 
observation led to the idea that  these receptors should be absent from 
this locus. However, we clearly demonstrate the presence of the 
receptor at the dopaminergic nerve ending by performing morphologic 
studies, which further confirm the presynaptic modulatory role of A2A 
receptors upon dopamine release (see 3.1.2).  
Regarding GDNF, it was necessary to determine which type(s) of 
nerve terminals are equipped with its receptor proteins, since a 
systematic study at the protein level has not been reported so far. 
Double immunocytochemical labelling of Ret or GFR1 with a marker of 
nerve terminals, synaptophysin, a protein located in synaptic vesicles, 
showed that a high proportion of the nerve endings at the striatum 
possess GDNF receptor complex. However, only few GABAergic and 
cholinergic terminals were endowed with Ret or GFR1 immunoreactivity, 
in contrast to the numerous dopaminergic and glutamatergic terminals 
immunopositive for GDNF receptor proteins, which may suggest a major 
role for GDNF in the control of dopamine and glutamate release. Studies 
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on the subsynaptic localization of Ret and GFR1 revealed that the 
proteins are mainly located in the presynaptic active zone fraction 
(where neurotransmitter release takes place, in agreement with the 
presynaptic modulatory role proposed for GDNF) and in the postsynaptic 
density and have a significantly lower relative abundance in the 
extrasynaptic fraction of nerve terminals. 
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4. CONCLUSION 
 
The main goal of the present work was to investigate the possible 
modulation role of adenosine A2A receptors of the GDNF-mediated 
effects at the neurotransmitter release level in the striatum. The main 
conclusions are that: (a) GDNF facilitates dopamine and glutamate 
release in a manner dependent on adenosine A2A receptor activation; (b) 
in vivo stimulation of the cortical (glutamatergic) afferents triggers 
phosphorylation of the GDNF receptor protein, Ret, in the striatum, an 
effect that requires the tonic activation of A2A receptors; (c) GDNF 
receptor proteins are located in striatal nerve terminals, mainly 
glutamatergic and dopaminergic, and are co-located with adenosine A2A 
receptors.  
After the publication of the first results included in this thesis, 
namely on the functional interaction between GDNF and adenosine 
(Gomes et al., 2006), Yamagata et al. (2007) found that adenosine 
regulates GDNF expression and production in primary cultures of rat 
astrocytes. To date, these are the only reports firmly establishing a 
relation between adenosine and GDNF. Thus, the observations detailed 
in the present thesis provide a first evidence for a functional crosstalk 
between adenosine A2A receptors and GDNF and allow ascribing a novel 
role for GDNF in the striatum, acting on a short time scale as a 
presynaptic neuromodulator, apart from acting in a larger time scale 
as a trophic factor. In fact, we now report that GDNF presynaptically 
controls the release of dopamine and glutamate, in accordance with the 
localization of the GDNF receptor proteins in dopaminergic and 
glutamatergic terminals. This ability of GDNF to modulate 
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neurotransmitter release seems restricted to the control of glutamate 
and dopamine since only few GABAergic and cholinergic terminals were 
endowed with Ret/GFR1 immunoreactivity.  
In contrast with what occurs in cholinergic and GABAergic striatal 
nerve endings (Kirk and Richardson, 1994), dopamine release from 
striatal nerve endings is not under control of adenosine A2A receptors 
(Jin et al., 1993; Lupica et al., 1990 and present results), which led to the 
concept that these receptors might be absent from striatal dopaminergic 
nerve endings. However, we clearly show that A2A receptors in striatal 
dopaminergic nerve terminals modulate the action of GDNF on 
dopamine release. Therefore, the role of A2A receptors in the 
dopaminergic nerve endings might be as modulators of the action of 
other presynaptic receptors, rather than exerting a direct modulation of 
dopamine release. A2A receptors localized in glutamatergic nerve 
terminals form heteromers with A1 receptors and function as a 
concentration-dependent switch, by which fluctuations in adenosine 
concentrations inhibit (by acting at A1 receptors) or facilitate glutamate 
release (Ciruela et al., 2006; Ferré et al., 2007). The present results 
indicate that GDNF can provide an additional key component for the 
operation of the A1-A2A receptor heteromer, reinforcing the idea (see 
Sebastião and Ribeiro, 2000) that a main role of A2A receptors in 
different brain areas is to interact with receptors for other 
neuromodulators, a process probably involved in the fine tuning of 
neuronal function.  
The observation that GDNF controls the two key transmitter 
systems involved in defining the firing pattern of striatal circuits has 
profound implications for the conception of the role of GDNF in striatal 
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circuitry. This simultaneous ability of GDNF to presynaptically control the 
release of glutamate (the trigger of striatal circuits) as well as the release 
of dopamine (the main modulator defining the ON state of the targeted 
medium spiny neurons) predicts a powerful effect of GDNF on striatal 
plasticity, which is considered a key event both in striatal physiology 
as well as major adapting and contributing factor in neurodegenerative 
diseases affecting striatal circuits (Calabresi et al., 2007). Whereas it is 
known that A2A receptors control synaptic plasticity in the basal ganglia 
(D‟Alcantara et al., 2001), it remains to be defined if GDNF participates 
in synaptic plasticity changes at corticostriatal synapses in an adenosine 
A2A receptor dependent manner. Likewise, the functional interaction 
between A2A receptors and GDNF to control the demise of 
neurodegenerative processes affecting striatal circuits should also be 
considered. The beneficial role of GDNF in different neurodegenerative 
diseases affecting striatal circuits can be adequately explained by 
considering the direct effects of GDNF within the striatum and, according 
to the present data, in glutamatergic and dopaminergic terminals. 
However, the present findings that the tonic activation of A2A receptors 
determines the activation and function of the GDNF modulation system, 
clearly point towards the need of further studies on the consequences of 
long-term therapy with A2A receptor blockers in neurodegenerative 
diseases where GDNF may have a beneficial role.  
These in vitro observations were extended with in vivo studies 
further supporting the pivotal role of A2A receptors to enable the 
functioning of the modulation system operated by GDNF. Thus, I 
observed that cortical stimulation increased Ret phosphorylation in the 
striatum compared to electrode-implanted non-stimulated controls, an 
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effect counteracted by A2A receptor antagonism. These results indicate 
that stimulation of cortical afferents promotes activation of the effector of 
the GDNF receptor in the striatum, a process that requires co-activation 
of A2A receptors. The ability of the GNDF system to facilitate 
neurotransmitter release and to become activated upon recruitment of 
the corticostriatal pathway suggests that GDNF might be part of a 
positive feedback loop potentiating corticostriatal transmission. This loop 
is under tight control by adenosine A2A receptor, so that GDNF facilitates 
the release of transmitters, which in turn may result in enhanced 
synaptic activity and further facilitates activation of the GDNF receptor 
complex (Figure 4.1). 
Finally, I obtained direct morphological evidence to support the 
tight interaction between A2A and GDNF receptors, showing for the first 
time the co-location of GDNF and A2A receptors at both dopaminergic 
and glutamatergic terminals in the striatum.  
In summary, I now provide the first direct morphological evidence 
indicating that GDNF receptor proteins are located in striatal 
glutamatergic and dopaminergic nerve terminals and that these 
receptors are co-located with A2A receptors in a subset of these 
terminals. This supports the ability of GDNF to facilitate dopamine and 
glutamate release in a manner dependent on the activation of A2A 
receptors in both dopaminergic and glutamatergic nerve terminals. 
Phosphorylation of Ret, the first step of the transducing signalling 
triggered by GDNF after binding to its receptor, also requires co-
activation of A2A receptors, further suggesting that GDNF actions in the 
striatum are seriously impaired when A2A receptors are not free to be 
activated by its endogenous ligand. Altogether, these findings prompt a 
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novel view on the role of GDNF in striatal circuits, where it fulfils a 
synaptic short term neuromodulation role apart from its long term role as 
a neurotrophic factor. Furthermore, the synaptic localization of the 
GDNF modulation system controlling glutamatergic synapses in a 
manner tightly controlled by A2A receptors opens a novel working 
hypothesis to understand the control of synaptic plasticity and 
neurodegeneration by these two receptor systems. 
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Figure 4.1 - Hypothetical model for a new role of adenosine A2A receptor in striatal 
physiology - focus on the functional interaction and receptor co-localization with 
GDNF. A. Neuronal inputs (glutamatergic and dopaminergic from cortex and substantia 
nigra pars compacta) to the striatum and stimulation of the corticostriatal glutamatergic 
efferents. B. A magnified scheme of presynaptic  glutamatergic (1) and dopaminergic (2) 
terminals, showing A2AR-mediated Ret phosphorylation, subsequent to the corticostriatal 
stimulation and the overall result, neurotransmitter release. 
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